CA2303483A1 - Sag: sensitive to apoptosis gene - Google Patents

Abstract

The present invention provides novel genes and polypeptides derived therefrom encoding a redox-sensitive protein that promotes cell growth, protects cells from apoptosis, scavenges oxygen radicals and can be used for the reversion of a tumor phenotype. In an attempt to identify gene(s) responsible for 1,10-phenanthroline (OP)-induced apoptosis in tumor cells we have used the differential display technique and cloned an OP-inducible gene, SAG (Sensitive to Apoptosis Gene). SAG encodes a novel, redox-sensitive, heme-binding protein with a zinc RING finger domain. The SAG protein consists of 113 amino acids with a calculated molecular weight of 12.7 kDa. Antisense SAG transfection inhibits certain tumor cell phenotypes in DLD1 human cell line and microinjection of SAG RNA stimulates cell growth. We propose that SAG protein is a cellular protective molecule functioning as a redox sensor to buffer oxidative-stress induced damage as well as a growth factor to stimulate cell growth. SAG protein will be an ideal molecular target in the development of drugs against neurodegenerative disorders, cancers, muscle dystrophy, and promoting wound healing.

Description

SAG: SENSITIVE TO APOPTOSIS GENE
Background of the Invention The present invention relates to a novel gene and polypeptides derived therefrom encoding a redox-sensitive protein that protects cells from apoptosis and promotes cell growth, as well as antibodies directed against the polypeptide. The invention also describes methods for using the novel gene, polypeptides, and antibodies in the detection of genetic deletions of the gene, subcellular localization of the polypeptide, isolation of discrete classes of RNA, inhibition of apoptosis, scavenging of oxygen radicals, reversion of tumor phenotype, and therapeutic applications by gene therapy.
Summary of the Related Art Apoptosis, also referred to as programmed cell death, is a genetically programmed process for maintaining homeostasis under physiological conditions and for responding to various stimuli (Thompson (1995) Science 267, 1456-1462). This form of cell death is characterized by cell membrane blebbing, cytoplasmic shrinkage, nuclear chromatin I S condensation, and DNA fragmentation (Wyllie ( 1980) Int. Rev. Cytol. 68, 251-306). The process of apoptosis can be divided into three distinct phases: initiation, effector molecule stimulation and DNA degradation (Kroemer et al. (1995) FASEB J. 9, 1277-1287;
Vaux and Strasser (1996) Proc. Natl. Acad. Sci. USA 93, 2239-2244). Apoptosis can be initiated in various cell types by a wide variety of physical, chemical, and biological stimuli (both internal and external), including diverse cancer therapeutic drugs, oxidative DNA damage reagents, and cytokines (Kroemer (1997) Nature Med. 3, 614-620, White (1996) Genes Dev.
10, 1-15; Sen and D'Incalci (1992) FEBS Lett. 307, 122-127; Dive and Hickman (1991) Br.
J. Cancer 64, 192-196; Yuan et al. (1993) Cell 75, 641-652). These initiators trigger the effector molecules in cells leading to apoptotic signal transduction and amplification, which ultimately results in irreversible DNA degradation and cell death.
Many genes are involved in the apoptotic process. In general, the products of these genes are classified as either inducers or inhibitors of apoptosis. The balance between the activities of apoptosis inducers and inhibitors in a given cell determines whether that cell undergoes apoptosis. Among the growing list of apoptotic regulatory genes, the most well characterized are the p53 tumor suppressor gene, the Bcl-2 gene family (consisting of both inducers and inhibitors of apoptosis), the interleukin 1 (3 converting enzyme (ICE) gene family, and FAS/Fas ligand (Kroemer ( 1997), White ( 1996); Yuan et al. ( 1993 ); Nagata and Golstein (1995) Science 267, 1449-I456). During apoptosis, there are substantial interactions involving the products of apoptotic regulatory genes, including heterodimer formation among the gene products of the Bcl-2 gene family, and p53 activation of Bax expression (Oltvai et al. (I993) Cell 74, 609-619; Miyashita and Reed (1995) Cell 80, 293-299).
The inventor has recently found that 1,10 phenanthroline ("OP"), a metal cheIating agent, can activate p53 activity and induce apoptosis in two marine tumor cell lines that harbor endogenous wild-type p53 (Sun et al. (1997) Oncogene 14, 385-393). OP
is a typical metal chelating reagent in that it chelates Fe(II) and prevents Fe(II)-mediated hydroxyl radical formation through the Fenton reaction (Halliwell et al. (1989) in:
Free Radicals in Biology and Medicine, 2nd ed., Clarendon Press, Oxford; Auld (1988) in Methods in Enzymology, Vol. 158 (J. F. Riordan and B. L. Valle, Eds.) PP. 110-114, Academic Press, New York). OP has been shown to prevent hydroxyl radical-induced DNA damage in a number of cellular systems (Sun, Y. Free Radic. Biol. Med. 8:583-599 (1990);
Martins and Meneghini, Biochem J. 299:137-140 (1994}; Morgan et al., Biochem. Pharmacol.
44:215-221 (1992)). Activation of p53 by OP was found to significantly contribute to, but was not required for subsequent apoptotic cell death (Sun et al., (1997) Oncogene 14:
385-393; Sun (1997) FEBS Lett. 408, 16-20). Thus, the critical genes and gene products responsible for OP-induced apoptosis remain to be characterized. A better understanding of the molecular mechanisms of apoptotic induction will allow improved design of therapeutic drugs that either induce (anti-cancer) or inhibit (anti-aging) apoptosis.
Summary of the Invention The present invention provides novel genes and polypeptides derived therefrom encoding a redox-sensitive protein that protects cells from apoptosis, scavenges oxygen radicals, and can be used for the reversion of a tumor phenotype.
In one aspect, the present invention provides novel isolated and purified DNA
sequences (referred to herein as "mouse SAG" and "human SAG") as shown in SEQ

and SEQ ID 3, and their gene products (referred to herein as "mouse SAG
protein" and "human SAG protein") as shown in SEQ ID 2 and SEQ ID 4, that are induced during I,IO-phenanthroline ("OP")-induced apoptosis. In another embodiment, the present invention comprises a nucleotide sequence that hybridizes to the nucleotide sequence shown in SEQ ID I and SEQ ID 3 under high stringency hybridization conditions. In a preferred embodiment, the isolated and purified DNA sequence consists essentially of the DNA
sequence of SEQ ID 1 or SEQ ID 3.

In another aspect, the invention provides novel recombinant DNA molecules, comprising SAG subcloned into an extra-chromosomal vector. In a further aspect, the present invention provides recombinant host cells that are stably transfected with a recombinant DNA molecule comprising SAG subcloned into an extra-chromosomal vector.
In a different aspect, the present invention provides a substantially purified recombinant protein comprising a polypeptide substantially similar to the SAG
protein shown in SEQ ID 2 and SEQ ID 4. In a further aspect, the present invention provides a polyclonal antibody that selectively binds to proteins with an amino acid sequence substantially similar to the amino acid sequence shown in SEQ ID 2 and SEQ ID 4.
Additional aspects of the present invention provide a method of detecting the SAG
protein in cells, comprising contacting cells with a polyclonal antibody that recognizes the SAG protein; a method of detecting cells containing SAG deletions, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR
amplification using primers derived from the DNA sequence of SEQ ID l and SEQ ID 3; and a method of detecting cells containing SAG deletions, comprising isolating total cell RNA
and subjecting the RNA to reverse transcription-PCR amplification using primers derived from the DNA
sequence of SEQ ID 1 and SEQ ID 3.
In another aspect, the present invention further provides methods of isolating RNA
containing stretches of polyA, polyC, or polyU residues from cells, contacting the total cell RNA with the SAG protein, and incubating the RNA-SAG protein mixture with an antibody that recognizes the SAG protein.
In another aspect of the present invention, a method for isolating genes induced during cell apoptosis is provided, comprising treating cells with OP, subjecting the OP-induced RNA to the differential display procedure, and cloning the OP-induced genes.
A further aspect of the invention provides a method for protecting mammalian and/or non-mammalian cells from apoptosis induced by redox reagents, comprising introducing into mammalian and/or non-mammalian cells an expression vector comprising a DNA
sequence substantially similar to the DNA sequence shown in SEQ ID 1 and SEQ ID 3, which is operatively linked to a DNA sequence that promotes the expression of the DNA
sequence, wherein the isolated and purified DNA sequence of SEQ ID 1 and SEQ ID 3 will be expressed at high levels in the mammalian and/or non-mammalian cells.
An additional aspect of the present invention provides a method for treatment of mammalian and/or non-mammalian tumor cells, comprising introducing into mammalian and/or non-mammalian tumor cells an expression vector comprising a DNA
sequence substantially similar to the DNA sequence shown in SEQ ID 1 and SEQ ID 3, which is operatively linked to a DNA sequence that promotes the expression of the antisense strand of the DNA sequence, wherein the antisense strand of the DNA sequence of SEQ ID 1 and SEQ
ID 3 will be expressed at high levels in the mammalian and/or non-mammalian cells.
Another aspect of the present invention provides a method for oxygen radical scavenging in an organism, comprising administering an oxygen radical-reducing amount of a pharmaceutical composition comprising SAG protein and a pharmaceutically acceptable carrier.
A further aspect of the present invention provides for gene therapy applications of SAG, including but not limited to methods of promoting the closure (i.e., healing) of a wound in a patient.
The foregoing is not intended and should not be construed as limiting the invention in any way. All patents and publications cited herein are incorporated by reference in their entirety.
Brief Description of the Drawings Figure lA. Predicted structural features of the deduced protein sequence of the mouse and human SAG cDNA.
Figure 1B. Description of human SAG protein mutants.
Figure 2. Bar graph depiction of soft agar colony growth of various SAG-transfected stable cell lines.
Figure 3. Graphical representation of tumor mass in SCID mice per days post implant with SAG transfectants.
Detailed Description of the Invention The present invention provides novel genes and polypeptides derived therefrom encoding a redox-sensitive protein that protects cells from apoptosis, scavenges oxygen radicals, and can be used for the reversion of a tumor phenotype. The present invention also comprises genes and their gene products involved in OP-induced apoptosis. The isolation of such genes and their gene products permits a detailed analysis of the OP-induced apoptotic pathway, thus providing laboratory tools useful to identify the mechanisms of OP-induced apoptosis and enabling improved design of therapeutic drugs to regulate apoptosis.
Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: Molecular Cloning: A
Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in Methods in Enzymology (M.P.
Deutshcer, ed., (I990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications S (Innis, et al. 1990. Academic Press, San Diego, CA), Culture of Animal Cells: A Manual of Basic Technigue, 2nd Ed. (R.I. Freshney. 198?. Liss, Inc. New York, NY), and Gene Transfer and Expression Protocols, pp. 109-128, ed. E.J. Murray, The Humans Press Inc., Clifton, N.J.).
In one aspect, the present invention provides novel isolated and purified DNA
sequences, hereinafter referred to as Sensitive to Apoptosis Genes ("SAG"), encoding SAG
proteins. In one embodiment, the invention comprises DNA sequences substantially similar to those shown in SEQ ID 1 (mouse SAG) or SEQ ID 2 (human SAG), respectively.
As defined herein, "substantially similar" includes identical sequences, as well as deletions, substitutions or additions to a DNA, RNA or protein sequence that maintain the function of the protein product and possess similar zinc-binding motifs. Preferably, the DNA sequences according to the invention consist essentially of the DNA sequence of SEQ ID 1 or SEQ ID
3, or are selected from the group consisting of SEQ ID 11, SEQ ID 13, SEQ ID
21, SEQ ID
23, SEQ ID 25, SEQ ID 27, SEQ ID 29, SEQ ID 31, SEQ ID 33, SEQ ID 35, SEQ ID
37, SEQ ID 39, SEQ ID 41, SEQ ID 43, SEQ ID 45, SEQ ID 47 and SEQ ID 49. These novel purified and isolated DNA sequences can be used to direct expression of the SAG protein and for mutational analysis of SAG protein function.
Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein, as described in Example 8, infra, and techniques well known in the art.
In another embodiment, the invention comprises a nucleotide sequence that hybridizes to SEQ ID 1 and/or SEQ ID 3 under high stringency hybridization conditions. As used herein, the term "high stringency hybridization conditions" refers to hybridization at 65°C in a low salt hybridization buffer to the probe of interest at 2 x 108 cpm/~,g for between about 8 hours to 24 hours, followed by washing in 1 % SDS, 20 mM phosphate buffer and 1 mM
EDTA at 65°C, for between about 30 minutes to 4 hours. In a preferred embodiment, the low salt hybridization buffer comprises between, 0.5-10% SDS, and O.OSM and 0.5 M
sodium phosphate. In a most preferred embodiment, the low salt hybridization buffer comprises, 7%
SDS, and 0.125M sodium phosphate. These DNA sequences can be used to direct expression of the SAG protein and for mutational analysis of SAG protein function, and are isolated via hybridization as described.
In another aspect, the invention provides novel recombinant DNA molecules, comprising SAG or a sequence substantially similar to it subcloned into an extra-chromosomal vector. This aspect of the invention allows for in vitro expression of the SAG
gene, thus permitting an analysis of SAG gene regulation and SAG protein structure and function. As used herein, the term "extra-chromosomal vector" includes, but is not limited to, plasmids, bacteriophages, cosmids, retroviruses and artificial chromosomes. In a preferred embodiment, the extra-chromosomal vector comprises an expression vector that allows for SAG pmtein production when the recombinant DNA molecule is inserted into a host cell. Such vectors are well known in the art and include, but are not limited to, those with the T3 or T7 polymerise promoters, the SV40 promoter, the CMV promoter, or any promoter that either can direct gene expression, or that one wishes to test for the ability to direct gene expression. These recombinant vectors are produced via standard recombinant DNA protocols as described in the references cited above. This aspect of the invention allows for high level expression of the SAG protein.
In a further aspect, the present invention provides recombinant host cells that are stably transfected with a recombinant DNA molecule comprising SAG subcloned into an extra-chromosomal vector. The host cells of the present invention may be of any type, including, but not limited to, non-eukaryotic (e.g., bacterial), and eukaryotic such as fungal (e.g., yeast), plant, non-human animal, non-human mammalian (e.g., rabbit, porcine, mouse, horse) and human cells. Transfection of host cells with recombinant DNA
molecules is well known in the art (Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, 1989) and, as used herein, includes, but is not limited to calcium phosphate transfection, dextrin sulfate transfection, electroporation, lipofection and viral infection. This aspect of the invention allows for in vitro and in vivo expression of SAG and its gene product, thus enabling high-level expression of SAG protein, as described in Example 6, infra.
In another aspect, the present invention provides a substantially purified recombinant protein comprising a polypeptide substantially similar to the SAG polypeptides shown in SEQ ID 2 and SEQ ID 4. Furthermore, this aspect of the invention enables the use of SAG
protein in several in vitro assays described below. As used herein, the term "substantially similar" includes deletions, substitutions and additions to the sequences of SEQ IDs 1-4 (as appropriate) introduced by any in vitro means. As used herein, the tenor "substantially purified" means that the protein should be free finm detectable contaminating protein, but the SAG protein may be co-purif ed with an interacting protein, or as an oligomer.
Preferably, the protein sequences according to the invention comprise an amino acid sequence selected from the group consisting of SEQ ID 2, SEQ ID 4, SEQ ID 12, SEQ ID 14, SEQ ID
22, SEQ
ID 24, SEQ ID 26, SEQ ID 28, SEQ ID 30, SEQ ID 32, SEQ ID 34, SEQ ID 36, SEQ
ID 38, SEQ ID 40, SEQ ID 42, SEQ ID 44, SEQ ID 46, SEQ ID 48, and SEQ ID 50. In a most preferred embodiment, the protein sequences according to the invention comprise an amino acid sequence selected from the group consisting of SEQ ID 2 and SEQ ID 4.
Mutated sequences according to the invention can be identified in a routine manner by those skilled in the art using the teachings provided herein and techniques well known in the art. This aspect of the invention provides a novel purified protein that can be used for in vitro assays, as described in Examples 12, infra, and as a component of a pharmaceutical composition for oxygen radical scavenging, described infra.
In a further aspect, the present invention provides antibodies and methods for detecting antibodies that selectively bind polypeptides with an amino acid sequence substantially similar to the amino acid sequence of SEQ ID 2 and SEQ ID 4. The antibody of the present invention can be a polyclonal or a monoclonal antibody, prepared by using all or part of the sequence of SEQ ID 2 or SEQ LD 4, or modified portions thereof, to elicit an immune response in a host animal according to standard techniques (Harlow and Lane (1988}, eds. Antibody: A Laboratory Manual, Cold Spring Harbor Press). In a preferred embodiment, the entire polypeptide sequence of SEQ ID 2 or SEQ ID 4 is used to elicit the production of polyclonal antibodies in a host animal.
The method of detecting SAG antibodies comprises contacting cells with an antibody that recognizes SAG protein and incubating the cells in a manner that allows for detection of the SAG protein-antibody complex. Standard conditions for antibody detection of antigen can be used to accomplish this aspect of the invention (Harlow and Lane, 1988). This aspect of the invention permits the detection of SAG protein both in vitro and in vivo, as described in Examples 12 and 14, infra.
In a fiu~ther aspect, the present invention provides a diagnostic assay for detecting cells containing SAG deletions, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR amplification using primers derived from the DNA
sequence of SEQ ID 1 SEQ ID 3, SEQ ID 11, SEQ ID 13, SEQ ID 21, SEQ ID 23, SEQ

WO 99/32514 PC"T/US98/26705 ID 25, SEQ ID 27, SEQ ID 29, SEQ ID 31, SEQ ID 33, SEQ ID 35, SEQ ID 37, SEQ
ID 39, SEQ ID 41, SEQ ID 43, SEQ ID 45, SEQ ID 47 and SEQ ID 49.
This aspect of the invention enables the detection of SAG deletions in any type of cell, and can be used in genetic testing or as a laboratory tool. The PCR
primers can be chosen in any manner that allows the amplification of a SAG gene fragment large enough to be detected by gel electrophoresis. Detection can be by any method, including, but not limited to ethidium bromide staining of agarose or polyacrylamide gels, autoradiographic detection of radio-labeled SAG gene fragments, Southern blot hybridization, and DNA
sequence analysis. In a preferred embodiment, detection is accomplished by polyacrylamide gel electrophoresis, followed by DNA sequence analysis to verify the identity of the deletions. PCR conditions are routinely determined based on the length and base-content of the primers selected according to techniques well known in the art (Sarnbrook et al., 1989).
An additional aspect of the present invention provides a diagnostic assay for detecting cells containing SAG deletions, comprising isolating total cell RNA and subjecting the RNA
to reverse transcription-PCR amplification using primers derived from the DNA
sequence of SEQ ID 1 SEQ ID 3, SEQ ID 11, SEQ ID 13, SEQ ID 21, SEQ ID 23, SEQ ID 25, SEQ
ID 27, SEQ ID 29, SEQ ID 31, SEQ ID 33, SEQ ID 35, SEQ ID 37, SEQ ID 39, SEQ
ID 41, SEQ ID 43, SEQ ID 45, SEQ ID 47 and SEQ ID 49. This aspect of the invention enables the detection of SAG deletions in any type of cell, and can be used in genetic testing or as a laboratory tool.
Reverse transcription is routinely accomplished via standards techniques (Ausubel et al., in Current Protocols in Molecular Biology, ed. John Wiley and Sons, Inc., 1994) and PCR is accomplished as described above.
In another aspect, the present invention provides methods of isolating RNA
containing stretches of polyA (adenine), polyC (cytosine) or polyU (uridine) residues, comprising contacting an RNA sample with SAG protein, incubating the RNA-SAG
protein mixture with an antibody that recognizes the SAG polypeptide, isolating the antibody-SAG
protein-RNA complexes, and purifying the RNA away from the antibody-SAG
protein complex. This aspect of the invention provides a novel in vitro method for isolating a discrete class of RNA. In a preferred embodiment, the RNA sample is contacted with SAG
protein in the presence {for preferential isolation of polyA and polyC-containing RNAs), or absence {for preferential isolation of polyU-containing RNAs), of a reducing agent. Preferred reducing agents for use in this aspect of the invention include, but are not limited to DTT and (3-mercaptoethanol. The reducing agents are preferably used at a concentration of between about 50 mM and 1 M. Isolation of antibody-SAG protein-RNA complexes can be accomplished via standard techniques in the art, including, but not limited to the use of Protein-A conjugated to agarose or cellulose beads.
In a further aspect of the present invention, a method for isolating genes induced during cell apoptosis is provided, comprising treating one set of cells with OP and not treating a control set of cells, isolating RNA from each set of cells, subjecting the RNA from each set of cells to reverse transcription and PCR ("differential display"), identifying cDNAs that are expressed in the OP-treated set of cells and not in the control set of cells, and cloning the OP-induced cDNAs. This aspect of the invention provides a tool for isolating other genes that control the OP-induced apoptotic pathway and is useful both as a way to enable the design of therapeutic drugs that regulate apoptosis and as a laboratory tool to identify the mechanisms of OP-induced apoptosis. Details of the differential display technique, including selection of primers, are well known in the art (Liang and Pardee, Science 257:967-971, 1992). Reverse transcription and PCR conditions are routinely determined based on the length and base-content of the primers selected according to techniques well known in the art (Sambrook et al., 1989). In a preferred embodiment, OP is used at a concentration of between 50 ~M and 300 ~,M. In a most preferred embodiment, OP is used at a concentration of between 100 ~t,M and 150 N.M.
A further aspect of the invention provides a method for protecting mammalian and/or non-mammalian cells from apoptosis induced by redox reagents, comprising introducing into mammalian and/or non-mammalian cells an expression vector comprising a DNA
sequence substantially similar to the DNA sequence shown in SEQ ID 1 or SEQ ID 3, that is operatively linked to a DNA sequence that promotes the expression of the DNA
sequence and incubating the cells under conditions wherein the DNA sequence of SEQ ID 1 or will be expressed at high levels in the mammalian and/or non-mammalian cells.
In a preferred embodiment, the DNA sequence consist essentially of SEQ ID 1 or SEQ
ID 3.
Suitable expression vectors are as described above. In a preferred embodiment, the coding region of the human SAG gene is subcloned into an expression vector under the transcriptional control of the cytomegalovirus (CMV) promoter to allow for constitutive SAG
gene expression.
An additional aspect of the present invention provides a method for inhibiting the growth of mammalian and/or non-mammalian tumor cells, comprising introducing into mammalian and/or non-mammalian tumor cells an expression vector comprising a DNA that is antisense to a sequence substantially similar to the DNA sequence shown in SEQ ID 1 or SEQ ID 3 that is operatively linked to a DNA sequence that promotes the expression of the antisense DNA sequence. The cells are then grown under conditions wherein the antisense DNA sequence of SEQ ID 1 or SEQ ID 3 will be expressed at high levels in the mammalian and/or non-mammalian cells. In a preferred embodiment, the DNA sequence consists essentially of SEQ ID 1, SEQ ID 3, SEQ ID 11, SEQ ID 13, SEQ ID 21, SEQ ID 23, SEQ ID
25, SEQ ID 27, SEQ ID 29, SEQ ID 31, SEQ ID 33, SEQ ID 35, SEQ ID 37, SEQ ID
39, SEQ ID 41, SEQ ID 43, SEQ ID 45, SEQ ID 47 and SEQ ID 49. -In a most preferred embodiment, the DNA sequence consists essentially of SEQ

or SEQ ID 3. In a further preferred embodiment, the expression vector comprises an adenoviral vector wherein SAG cDNA is operatively linked in an antisense orientation to a cytomegalovirus (CMV) promoter to allow for constitutive expression of the SAG
antisense cDNA in a host cell. In a preferred embodiment, the SAG adenoviral expression vector is introduced into mammalian tumor cells by injection into a mammalian tumor cell mass.
An additional aspect of the present invention provides a method for oxygen radical scavenging in an organism, comprising introducing into mammalian and/or non-mammalian cells an expression vector comprising a DNA sequence substantially similar to the DNA
sequence shown in SEQ ID 1 or SEQ ID 3 which is operatively linked to a DNA
sequence that promotes the expression of the DNA sequence, and the cells are grown under conditions wherein the DNA sequence of SEQ ID 1 or SEQ ID 3 will be expressed at high levels in the mammalian and/or non-mammalian cells. In a preferred embodiment, the DNA
sequence consists essentially of SEQ ID 1 or SEQ ID 3. In a preferred embodiment, the SAG cDNA is operatively linked to a cytomegalovirus (CMV) promoter, to allow for constitutive expression of the SAG cDNA in a host cell.
Another aspect of the present invention provides pharmaceutical compositions and methods for oxygen radical scavenging in an organism, comprising administering an oxygen-reducing amount of a pharmaceutical composition comprising the SAG protein of or SEQ ID 4 and a pharmaceutically acceptable carrier.
Chimeric gene constructs of the present invention (e.g., expression vectors) containing SAG polynucleotide sequences may be used in gene therapy applications to achieve expression of SAG or anti-sense SAG polynucleotide sequences in selected target cells, including non-eukaryotic cells (i.e., plant) and eukaryotic cells. Gene therapy applications typically involve identifying target host cells or tissues in need of the therapy, WO 99/32514 PC"T/ttS98l26705 designing vector constructs capable of expressing a desired gene product in the identified cells, and delivering the constructs to the cells in a manner that results in efficient transduction of the target cells.
The cells or tissues targeted by gene therapy are typically those that are affected by the disease that the vector construct is designed to treat. For example, in the case of cancer, the targeted tissues are malignant tumors.
In one embodiment, the present invention provides a method of promoting the closwe (i.e., healing) of a wound in a patient. This method involves transferring exogenous SAG to the region of the wound whereby a product of SAG is produced in the region of the wound to promote the closwe (i.e., healing) of the wound.
The present inventive method promotes closwe (i.e., healing) of both external (e.g., surface) and internal wounds. Wounds to which the present inventive method is useful in promoting closwe (e.g., healing) include, but are not limited to, abrasions, avulsions, blowing wounds, burn wounds, contusions, gunshot wounds, incised wounds, open wounds, penetrating wounds, perforating wounds, puncture wounds, seton wounds, stab wounds, surgical wounds, subcutaneous wounds, tangential wounds, or traumatopneic wounds.
Preferably, the present inventive methods are employed to close chronic open wounds, such as non-healing external ulcers and the like.
Exogenous SAG can be introduced into the region of the wound by any appropriate means, such as, for example, those means described herein. For example, where the wound is a surface wound, SAG can be supplied exogenously by topical administration of SAG protein to the region of the wound.
Preferably, exogenous SAG is provided to the wound by transferring a vector comprising an SAG expression cassette to cells associated with the wound. Upon expression of SAG within the cells in the region of the wound, a product of SAG is produced to promote wound closure (i.e., healing). Transferring a vector comprising an SAG
expression cassette to cells associated with the wound is prefen~ed as such procedwe is minimally invasive, supplies SAG products locally within the region of the wound, and requires no reapplication of salves, solutions, or other extrinsic media. Furthermore, SAG activity remains expressed during wound closwe and will inactivate following healing.
The vector comprising the SAG expression cassette can be transferred to the cells associated with the wound in any manner appropriate to transfer the specific vector type to the cells, such as those methods discussed herein.

As discussed above, the cells associated with the wound to which the vector is transferred are any cells sufficiently connected with the wound such that expression of SAG
within those cells promotes wound closure (i.e., healing), such as cells within the wound or cells from other sources. In one embodiment, the cells are cells of the wound, and the present inventive method comprises transfer of the vector to the cells in situ.
In other embodiments, the cells are not the cells of the wound, but can be cells in an exogenous tissue, such as a graft, or can be cells in vitro. For example, to promote the healing of certain types of wounds, the cells associated with the wound can be cells within a graft, such as a skin graft. Transfer of the vector to the cells associated with the wound, thus involves transferring the vector to the cells within the graft ex vivo. For other wounds, the cells associated with the wound are ceps in vitro, and the cells are transferred to the region of the wound following transfer to them of a vector containing the SAG expression cassette.
The present inventive method applies to any patient having a wound. For example, the patient can be any animal, such as a mammal. Preferably, the patient is human.
In another embodiment, the present invention provides a method of inhibiting or promoting plant cell growth. The method involves the use of chimeric gene constructs to achieve expression of SAG, in the case of promoting growth of plants, or anti-sense SAG, in the case of inhibiting plants (i.e., weeds), polynucleotide sequences in selected target plant cells.
The dosage regimen for in vivo oxygen radical scavenging by the administration of SAG protein is based on a variety of factors, including the type of injury, the age, weight, sex, medical condition of the individual, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. In a preferred embodiment, the pharmaceutical composition comprises between 0.1 and 100 mg of SAG
protein. In a most preferred embodiment, the pharmaceutical composition comprises between 1 and 10 mg of SAG protein.
The SAG protein may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The SAG
protein may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.
While the SAG protein can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.
For administration, the SAG protein is ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The SAG
protein may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration.
Alternatively, the SAG protein may be dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions, ethanol, corn oil, peanut oil, cottonseed oil, °
sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.
In a preferred embodiment of the present invention, the SAG protein pharmaceutical composition is administered intramuscularly (IM) or intravenously (IV). A
suitable IM or IV
dose of active ingredient of SAG protein is 5 mg/mL administered daily. For IM
or IV
administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1%
to 2% by weight of the formulation, although it may comprise as much as 10%
w/w, but preferably not more than 5% w/w, and more preferably from 0.1 % to I % of the formulation.
The present invention may be better understood with reference to the accompanying examples that are intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.
Examples Example 1. Identification of an OP-inducible gene The differential display (DD) technique was employed to isolate genes responsible for or associated with OP-induced apoptosis in two marine tumor lines. Since OP induced-apoptosis can be visually detected at 12 hours post exposure (Sun, (1997) FEBS
Lett. 408:16-20), it was reasoned that genes) responsible for apoptosis induction should be up- or down-regulated prior to the appearance of apoptosis. Six hours of OP treatment was conducted, therefore, in one of these tumor lines followed by the DD analysis.

Mouse JB6 tumor line L-RT101 (an epidermal originated tumor cell line) was cultured in Minimal Essential Medium with Earle's salts (BRL) containing 5%
fetal calf serum (Sigma). H-Tx cells, a spontaneously transformed mouse liver line, were cultured in Dulbecco's Modified Eagle Medium containing 10% fetal calf serum and 1 mM
sodium pyruvate. Human colon carcinoma line DLD-1 was grown in 10% DMEM.
L-RT101 cells were treated with 150 uM OP for 6 hours and subjected to differential display analysis using DMSO-treated cells as a control. Briefly, total RNA was isolated from both OP-treated and control cells using RNAzoI solution (Tel-Test) according to the manufacturer's instructions, and subjected to reverse transcription (RT), performed as previously described (Sun et al. (1993) Mol. Carcinogenesis 8, 49-57), followed by the polymerase chain reaction (PCR). The primer used for reverse transcription (P
1 ) consisted of the sequence 5 AAGCTTTTTTITTI'TTTR (SEQ ID 5), wherein R consists of either adenine, guanine or cytosine. P1 was used as the downstream primer in the subsequent PCR
while the upstream primer consisted of the sequence AAGCTTrII~INNNNN (SEQ ID
6), 1 S wherein N consists of adenine, cytosine, guanine, or thymine.
Primers P 1 and P2 reproducibly detected differential expression between the control and OP-treated cells. The fragments reproducibly showing differential expression were PCR
amplified using the same primers and used as probes for Northern analysis (Sun et al. (1992) Cancer Res. 52:1907-1915) of both L-RT101 and H-Tx cells treated with OP (Sun (1997) FEBS Letters 408:16-20). Those fragments that were induced by OP (as determined by Northern analysis) were then subcloned into TA cloning vectors (In Vitmgen) according to the manufacturer's instructions, and sequenced by DNA Sequenase Version 2.0, according to the manufacturer's instructions (Amersham). The resulting clones comprise OP-inducible cDNA fragments.
Example 2. cDNA library screening and S'RACE
One of the OP-inducible clones was used as a probe to screen a mouse lung cDNA
library to clone the full length mouse SAG cDNA. Briefly, 1 x 106 recombinant plaques were plated onto 1% NZY in 150 mm plates (a total of 20). The recombinant phage DNA
was transferred to nitrocellulose membrane and hybridized with mouse SAG probe (2X108 cpm/P,g) in a hybridization solution containing SX SSC, SX Denhardt solution, 50 mM
sodium phosphate, and 100 ~.g/mL denatured DNA at 60°C for 16-18 hours.
The filter was then washed once for 5 min in a solution of 2XSSC/0.1 % SDS, once for 5 min in O.SXSSC/0.1% SDS, and twice O.1XSSC/0.1% SDS for 15 min.
The longest clone isolated was a 1.0 kilohase ("kb") fragment consisting of a partial open reading frame and the entire 3'-end untranslated region. A mouse brain Marathon-Ready cDNA (ClonTech) was screened via PCR amplification using a primer derived from the I kb fragment and another primer derived from the vector sequence, according to the protocol supplied with the cDNA library. This yielded a further 100 by fragment consisting of 5'-end untranslated sequence and some of the coding sequence. The derived cDNA clone consists of 1140 base pairs ("bp") (SEQ ID 1 ) that encode a novel deduced protein of 113 amino acids, containing 12 cysteine residues (SEQ ID 2). The open reading frame was preceded by 17 by upstream sequence. The start codon was located in a context that conformed 100% to the Kozak consensus sequence (Kozak,M. (1991) J. Biol. Chem.
266, 19867-19870). An in-frame stop codon was identified 72 by upstream of the start codon in the 5' untranslated region in one genomic clone (not shown). The 3'-end untranslated region consists of 792 by sequence with two polyadenylation signals (AATAAA). These data indicate that a near full length cDNA was isolated.
The mouse cDNA was used as a probe to screen a human HeLa cell cDNA library (Strategene) as described above. One positive clone was isolated and purified through two more cycle of screening. In this manner, a 754 by clone containing a polyadenylation signal at the 3' end was isolated (SEQ ID 3). The human cDNA also contains an open reading frame encoding a novel predicted 113 amino acid polypeptide containing 12 cysteine residues (SEQ ID 4). The sequence identity between the isolated mouse and human cDNAs is 82% in overall sequence and 94% in the coding region. At the protein level, they shared 96.5%
identity, with all 12 cysteine residues being conserved. Computer analysis of protein databases using the GCG program (Genetics Computing Group, Madison, WI) revealed that the encoded proteins share 70% identity with hypothetical proteins from yeast (accession #Z74876) and C-elegans (accession #80449).
Motif searching of the deduced protein sequences using the GCG program did not reveal any known functional domains. However, they each contain two imperfect heme binding sites (CXXCH, at codons 47-51 and 50-54) (Matthews, Prog. Biophys.
Mol. Biol.
45:1-56, 1985) and one imperfect C3HC4 zinc ring finger domain (Freemont et al., Cell 64:483-484, 1991) at the C-terminal of the molecule (Fig. lA) among other consensus motifs.
The second potential heme binding domain (Fig. 1 A) contains a substitution of arginine to histidine (amino acid 54). Since these two amino acids are structurally similar, this may constitute an authentic heme binding site. The zinc ring finger domain mismatch involves substitution of cysteine by histidine at amino acid 85. The ring finger domain in this protein is a C3H2C3 structure, rather than the consensus C3HC4 structure. Since cysteine and histidine residues are interchangeable in zinc binding (Berg and Shi, Science 271:1081, 1996;
Inouye et al., Science 278:103-106, 1997), the C3H2C3 domain in these proteins may comprise authentic zinc-binding sites. Significantly, these heme and zinc ring finger domains are 100% conserved among C. elegans, mouse and human. In yeast, only the last cysteine residue in C3H2C3 motif was not conserved. This evolutionary conservation of the heme and zinc-binding domains suggest their functional importance.
Other motifs identified in the deduced sequence of the SAG protein, when allowing for a single mismatch, include an aminoacyl-transfer RNA synthetase class II
motif (codons 54-63), a Kazal serine protease inhibitor family motif (codons 85-107), a Ly-6/U-par domain (codons 65-107), a prokaryotic membrane lipoprotein lipid attachment site (codons 16-27), and somatotropin, prolactin and related hormone motifs (codons 49-66).
These experiments thus resulted in the cloning of novel mouse and human genes that encode nearly identical, evolutionarily conserved protein that contain distinct heme and zinc binding motifs.
Example 3. SAG is inducible by OP in both mouse and human tumor cells To confirm that the cloned cDNAs are subject to OP induction, a Northern analysis was performed with RNAs isolated from mouse tumor lines L-RT101 and H-Tx, and human colon carcinoma line DLD-1. Subconfluent cells were treated with 150 N,M OP
for various times up to 24 hours and subjected to total RNA isolation. Fifteen ~,g of total RNA was subjected to Northern analysis using mouse SAG or human SAG cDNA as probes.
Both cloned mouse and human cDNAs detected an OP inducible transcript with a size of 1.2 kb and 0.9 kb, respectively. Since these genes were induced in the OP-induced apoptosis pathway, the genes were named Sensitive to Apoptosis Genes (hereinafter referred to as "SAG"), which encode SAG proteins.
Example 4. Tissue distribution and embryonic expression of SAG
SAG expression was next examined in multiple human tissues. The assays were performed as detailed previously (Sun et al. (1993) Mol. Carcinogenesis 8, 49-57; Sun et al., Proc. Natl. Acad. Sci. USA 90:2827-2831, 1993). Briefly, total RNA was isolated from multiple human tissues (ClonTech) and then subjected to Northern blot analysis using the mouse or human SAG cDNA as probes. SAG RNA was detected in all tissue examined including heart, brain, pancreas, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes. A
very high expression level was detected in heart, skeleton muscle and testis, which consume high levels of oxygen. Its tissue distribution and high level expression in oxygen-consuming tissues, and its induction by a redox sensitive compound (OP), implies that SAG encodes a redox sensitive protein.
Since SAG protein is evolutionarily conserved, the possible developmental role of SAG was tested by measuring SAG expression in mouse embryonic tissue (provided by Dr.
Tom Glaser, University of Michigan), using reverse transcription of total RNA
followed by PCR with the following primers: SAGTA.O1 5'-CGGGATCCCCATGGCCGACGTGAGG-3' (SEQ ID 7) and SAGT.02 5'-CGGGATCCTCATTTGCCGATTCTTTG-3' (SEQ ID 8), which flank the entire SAG coding region. The PCR reaction mixture for 11 samples contained 55 p,L of lOX buffer, 22 ~,L of 1.25 mM dNTP, 1.1 ~,L of SAGTA.O1 and SAGT.02, respectively, 5.5 ~,L of Taq DNA polymerase, 5.5 P,I, of 32P-dCTP and sterile water up to 495 Er.l. Into each tube which contains 5 ~.I, of first strand cDNA reverse-transcribed for total RNA isolated from mouse embryonic tissues (Sun et al.
(1997), Mol.
Carcinogenesis 8:49-57), 45 ~,L of reaction mixture was added and PCR was performed for 25 cycles (95°C for 45 sec, 60°C for 1 min and 72°C for 2 min). A 5 ~,L aliquot of the PCR
product was denatured and separated on a sequencing gel, which was dried and exposed to X-ray film.
SAG RNA was expressed in 9.5 day old to 19.5 day old whole mouse embryos, with a higher level of expression detected between days 9.5 and 11.5. These results suggest that SAG plays a role in embryonic development.
Example S. Cellular localization by immunofluorescence NIH3T3 cells (ATCC CRL 1658) were plated on coverslips in 24-well culture dishes and transfected by the calcium phosphate method according to standard techniques (Sambrook et al, 1989) with the following constructs: pcDNA3.1 (Invitrogen vector pcDNA
3 with a myc-his-tag); pcDNA3.1-SAG (human SAG cDNA subcloned into the BamHI
site of pcDNA3.1, downstream from the CMV promoter and upstream and in-frame with the myc-his-tag, such that upon expression, the resulting fusion protein consists of the SAG

protein followed by the myc-his tag at the carboxy-end of SAG); or pcDNA3.1-LacZ
(Invitrogen). Two days post-transfection, cells were washed once with cold PBS
and then fixed with 3% formaldehyde in PBS for 10 .minutes followed by 5 minutes in 1:1 methanol:acetone. The fixed cells were washed 4 times in PBS and incubated with antibody directed against the Myc-tag (Invitrogen 1:200 dilution) in PBS containing 1 %
BSA, 0.1 saponin, 2 ~,g/mL DAPI for 1 hour in the dark with shaking. Cells were then washed 4 times with 0.1% saponin in PBS and incubated with FITC-conjugated goat anti-mouse antibody (Jackson Laboratory, 1:100 dilution) for 1 hour in the same conditions as the first antibody.
After incubation cells were washed 4 times with 0.1 % saponin in PBS and twice with PBS.
The coverslips were then mounted to glass slides with non-fade mounting medium and analyzed using a Leita Dialux 20 microscope.
SAG fusion protein was detected in both the cytoplasm and nucleus, while the ~i-galactosidase control was expressed predominately in the cytoplasm. No immunofluorescence staining was detected with the vector-only control. The cytoplasmic/
nuclear localization of SAG was confirmed also in a SAG stable transfectant using both SAG
and myc-tag antibodies. These data demonstrate that exogenously expressed SAG
fusion proteins can be detected within transfected cells by using antibodies directed against an epitope fused to SAG protein.
Example 6. Expression and purification of SAG protein in bacteria The entire open reading frame of the human SAG cDNA was PCR amplified as described above and subcloned into the pETl l expression vector (Novogen) under control of the T7 promoter, yielding construct pETlla-hSAG. The sequence and orientation of the SAG DNA insert were confirmed by DNA sequencing. pETlla-hSAG was used to transform E. coli strain BL21 (Novagen, Inc.). Transformed cells were grown in LB media containing ampicillin (50 pg/mL). SAG expression was induced by 0.5 mM IPTG
and SAG
protein was found in inclusion bodies, which were subsequently isolated as follows.
Following IPTG induction, four liters of cells were grown for 4.5 hours at 37°C at a shaker setting of 150 rpm. Cell pellets were obtained by centrifugation at 5000 rpm for 10 minutes, and were resuspended in 100 mL TN buffer (20 mM Tris-HCI, pH 7.5, 50 mM
NaCI) containing 100 ~.M PMSF. The resuspended cell pellet was subsequently sonicated (15 sec/round for S rounds at a setting of 15 on Model 50 sonic disrnembrator, Fisher Scientific) and subjected to pressure of 2500 pounds/square inch on a French cell press, WO 99/32514 PCTNS98lZ6705 followed by addition of 1 mM MgCl2 and 10 mg of DNase I. The cell lysate was placed on ice for 30-60 minutes and then centrifuged at 18,000 rpm and the supernatant was disposed.
The pellet was seen to have 2 layers. The white layer on the top was carefully blown loose with TN buffer and removed. The remaining dark brown layer on the bottom was resuspended thoroughly in 15 mL of urea buffer (7 M urea, 20 mM Tris-HCI, pH
7.5, 200 mM NaCI) and allowed to sit overnight at room temperature. The resuspended cell pellet was vigorously homogneized with a serological pipette and then centrifuged at 40,000 rpm for 40 minutes using an SW50 ultracentrifuge rotor. The supernatant was collected and concentrated using a Centricon-10 concentrator to a volume of 5 mL and loaded onto a Sephacryl-100 column (100 cm long with a diameter of 2.5 cm) that had been equilibrated with urea buffer. The column was run at a rate of 0.25 mL/min and fractions were collected.
The early fractions containing a brownish color consisted of mostly the large molecular weight protein, as expected. They also contained a protein with the same size of SAG protein (approximately 13 kDa). Since SAG protein contains 12 cysteine residues, it follows that SAG protein may form oligomers when expressed in bacteria and thus may elute as a SAG
protein oligomer. Since SAG is a redox-sensitive protein, the DTT present in SDS sample buffer reduces SAG protein oligomers to monomer, leading to the detection of a fast migrating band. When early fractions were run in SDS-PAGE without DTT, the 13 kDa SAG protein band disappeared, and a 260 kDa band was detected, representing a SAG
protein 20-mer. This unique feature helped us to purify SAG protein. Early fractions were pooled and loaded on the same Sephacryl-100 column pre-equilibrated with 7M
urea and SmM DTT.
SAG protein oligomer was reduced to monomer by using DTT in the loading buffer and was eluted in the later fractions, thus separating it from high molecular weight contaminant proteins (eluted earlier). The brownish fractions were pooled and concentrated using a Centricon-10 to a volume of 5 mL. DTT was added to a concentration of 5 mM. The combined fractions were loaded onto an S-100 column (100 cm long with a diameter of 2.5 cm), that had been equilibrated with urea buffer plus 5 mM DTT. The column was run at a rate of 0.25 mL/min and fractions were collected. The fractions containing SAG protein are brownish in color, highly suggesting that SAG is a heme-containing protein.
The SAG
protein containing fractions and their sensitivity to DTT were confirmed by Western blot using SAG antibody. The brownish fractions were pooled and concentrated using a Centricon-10 concentrator to a volume of 2 mL. The resulting sample was dialyzed against 4liters of dialysis buffer (150 mM KCI, 20 mM Tris-HCI, pH 7.5) at 4°C
overnight to remove urea and DTT to yield refolded SAG protein. The dialyzed sample was loaded onto an S-100 column (100 cm long with a diameter of 2.5 cm), that had been equilibrated with dialysis buffer. The brownish fractions were pooled and concentrated using a Centricon-10 to a volume of 1 mL. The resulting sample was stored at 4°C. The protein concentration was determined by a BioRad protein assay. The purity of the samples was demonstrated in 10-20% SDS-PAGE. These data demonstrate the purification of recombinant SAG
protein.
Example 7. Redox Sensitivity of SAG Protein To confirm that purified recombinant SAG protein possesses the same redox sensitivity as it shows during protein purification, the sensitivity of refolded SAG to redox reagents was examined next. SAG protein (1 ~,g) was exposed to various concentrations of DTT (1 M, 300 mM, 100 mM, or 30 mM) or H202 (15 mM, SO mM, 150 mM or 450 mM) for 10 min before being separated by polyacrylamide gel electrophoresis (PAGE), followed by Western blot analysis. Alternatively, 10 ~g of SAG protein was incubated with 50 mM
H202 for 10, 30, 60 or 120 minutes followed by PAGE separation and Coomassie Blue staining.
Dimers of SAG protein are rather resistant to reducing reagent DTT since no significant dimer was reduced to monomer after DTT treatment. However, as little as 15 mM
H202 induces oligomerization of SAG protein, possibly through the formation of intermolecular disulfide bonds. The oligomerization is incubation-time dependent, as higher order SAG protein oligomers were detected upon increased incubation time.
Interestingly, a band migrating faster than the monomer form is observed upon H202 treatment, and the monomer form of SAG protein becomes a doublet, possibly due to the formation of intramolecular disulfide bonds.
In order to determine whether H202-induced SAG protein oligomerization can be reversed by DTT treatment, 1 ~.g of purified SAG protein was incubated with SO
mM H202 for 10 minutes, followed by a 10 minute incubation with either H202, 50 mM
DTT, 100 mM, 500 mM, or 1 M DTT. The samples were separated via PAGE followed by Western analysis.
The results demonstrated that H202-induced SAG protein oligomerization can be reversed by subsequent incubation with DTT in a dose dependent manner, indicating that SAG protein oligomerization is subject to redox regulation.

To confirm that SAG protein oligomerization and doublet formation is due to inter-and infra-molecular disulfide bond formation, respectively, SAG protein was treated, prior to H202 exposure, with 50 mM N-ethylmaleimide (NEM), an alkylating reagent that will alkylate the free SH-groups in SAG protein. Purified SAG protein ( 1 ~,g) was pre-incubated with 50 mM NEM or DMSO, or buffer only, for 10 minutes prior to H202 treatment. The samples were separated via PAGE, followed by Western blot analysis. Pre-incubation of SAG protein with DMSO did not affect H202-induced oligomerization and doublet formation, whereas NEM pre-treatment abolished H202 activity. Neither inter-(oligomerization) nor infra- (doublet monomer) disulfide bonds were formed, demonstrating that alkylation of the free SAG protein SH groups abolishes H202 sensitivity.
These data demonstrate that SAG protein is redox sensitive. It is subjected to both infra-and inter-molecular disulfide bond formation upon exposure to H202, as evidenced by both doublet and oligomer formation. These H202-induced changes can be reversed by subsequent treatment with reducing reagents, including DTT, or can be prevented by NEM
pretreatment.
It has also been observed that zinc can promote H202-induced oligomerization, although zinc itself did not induce oligomerization.
Example 8: Production of SAG mutants In order to understand the role of each particular cysteine residues in heme binding and SAG oligomerization, a series of single and double SAG mutants were made in heme binding sites as well as the zinc ring finger motif (see Figure 1B). To generate single point mutations in SAG cDNA, 15 pairs of sense and antisense primers were designed, which are partially complimentary and contain a desired point mutation. The wildtype SAG
cDNA
cloned into the pETI la vector at the Nhe I/Bam HI sites was used as the template for PCR
amplification. Two separate PCR reactions were conducted using a) primer SAG
P.OI
(S'-TATGGCTAGC ATGGCCGACGTGGAGG-3) (SEQ ID 9) and each of antisense primers and b) each of sense primers and SAG T.02 (SEQ ID 8), respectively.
The resultant PCR products that overlap with each other and contain a desired point mutation were mixed and served as templates for a third PCR. The primers used were SAG P.O1 and SAG T.02, which flank the entire encoding region of SAG cDNA. The PCR was performed as previously described (Sun et al. (1992) BioTechniques 12:639-640). The PCR
products were digested with restriction enzymes Nhe I and Bam HI and subcloned into the pETl la vector, which was digested with the same restriction enzymes. To generate SAG double mutants (MM 10, MM 13, MM 14, see Figure 1 B), a QuickChange site-directed mutagenesis kit was purchased from Strategene (La Jolla, CA) and used as instructed. All SAG
mutants generated were verified by DNA sequencing (SEQ ID 21, SEQ ID 23, SEQ ID 25, SEQ ID 27, SEQ ID
29, SEQ ID 31, SEQ ID 33, SEQ ID 35, SEQ ID 37, SEQ ID 39, SEQ ID 41, SEQ ID
43, SEQ ID 45, SEQ ID 47 and SEQ ID 49). The predicted mutant SAG proteins encoded by these mutant SAGS are shown in SEQ ID 22, SEQ ID 24, SEQ ID 26, SEQ ID 28, SEQ
ID 30, SEQ ID 32, SEQ ID 34, SEQ ID 36, SEQ ID 38, SEQ ID 40, SEQ ID 42, SEQ
ID 44, SEQ ID 46, SEQ ID 48, and SEQ ID 50.
Individual SAG mutant-expressing vectors were used to transform E. coli strain (Novagen, Inc.). Mutant SAG protein was expressed and purified as detailed in Example 6.
The fractions after a Sephacryl-I00 column were collected and analyzed on 8-25% Phast gels followed by Coomassie blue protein staining. The pure fraction containing mutant SAG
protein was dialyzed in 4 liters of 20 mM Tris-HCI, pH 7.5 and used for SAG
protein oligomerization studies.
Purified wildtype SAG protein is a heme-containing brownish protein (See Example 9}. Some of the purified SAG protein mutants were found to have either lost the brownish color (MM3 and MM13) or had decreased brownish color (MMI) compared to wildtype SAG protein. This color change indicates the loss or decrease of heme binding (Table I ).

TABLE 1. SUMMARY OF SAG MUTANTS
NAME MUTATION SITES) HEMS BINDING OLIGOMERIZATION

WT None +++ Yes MMl CA/heme ++ Yes MM2 CB/heme +++ Yes MM3 CA+g/heme +/- Yes MM4 C I /Zn-ring finger +++ Yes MMS C3/Zn-ring finger +++ Yes MM6 H4/Zn-ring finger +++ Yes MM7 HS/Zn-ring finger +++ Yes MM8 C6/Zn-ring finger +++ Yes MM9 C7/Zn-ring finger +++ Yes MM I 0 H4+5/Zn-ring fingers+++ Yes 1 &2 I i C2~Zn-ring finger +++ Yes MM12 Cc/protease inhibitor+++ Yes MM 13 C I +2/Zn-nng forger+/- Yes MM14 C7+g/Zn-ring finger +++ No MM15 I GADPH binding site +++ Yes To examine mutant SAG protein oligomerization, each mutant SAG protein as well as wildtype SAG was treated with 50 mM H202 for 10 min. All of the SAG mutants, except MM14, can be oligomerized upon exposure to H202. The mutant 14, which is a double mutants in positions of C7 and C8 in the zinc ring finger domain, becomes insensitive to oligomerization (Table I), indicating that these two positions are important for intermolecular disulfide bond formation.
Example 9. Heme measurement of SAG protein Heme content in SAG pmtein was measured as previously described (Rieske ( 1967) Methods in Enzymol. 76, 488-493). Briefly, 1 mg of purified SAG protein, along with cytochrome C, catalase, and BSA as controls, was extracted with cold acetone {0.5 mLs) After centrifugation the pellet was extracted sequentially with 0.5 mL of chloroform:methanol (2:1); 0.5 mL of cold acetone, and finally 0.5 mL of cold acetone containing 5 p,L of 2.4 N HCI. The acetone extracts were dried under speed-vac and dissolved in 0.5 mL of pyridine. After addition of 0.5 mL of 0.2 N NaOH, the solution was centrifuged briefly and clear supernatant was recovered. One drop of diluted potassium ferricyanide (0.05 M) was added to the supernatant and the absorbance was read at 556 nm in 1.0 mL quartz cuvettes using water as a blank. The solution was then reduced by adding 10 uL of 2 M DTT and absorbance was read at 556 nm, 587 nm and 550 nm, respectively.
Heme absorbance at 556, 587, and 550 nm'was observed in SAG protein, as well as in cytochrome C and catalase, but not in BSA. This result demonsh~ated that SAG
protein contains heme, but did not reveal the molar ratio between SAG protein and heme molecule.
Example 10. SAG protein antibody production Two polyclonal antibodies against SAG protein were generated using standard methods [by Zymed Laboratories, Inc. (San Francisco) under a service agreement with Warner-Lambert]. Briefly, the peptide antibody was generated as following. A
16-amino acid peptide (SAG-Pepl: QNNRCPLCQQDWVVQR) (SEQ ID 10) located in the C terminus of SAG protein (colons 95-110) was synthesized and purified via standard techniques. The purified peptide was conjugated to keyhole limpet hemocyanin (KLH) via cysteine residues. The conjugated peptide (0.5 mg) was emulsified with equal volume of Complete Freund Adjuvant (CFA) and subcutaneously injected into rabbit, followed by 4 boosts with 0.5 mg each in Incomplete Freund Adjuvant (IFA) at 3 week intervals. Rabbits were bled 10 days after the final boost and antiserum was collected. The same protocol was used for protein antibody production using purified human SAG protein as the antigen, prepared as described above.
Example I1. Analysis of SAG protein transcriptional regulatory activity SAG protein belongs to the zinc ring finger protein families by virtue of its motif (Saurin et al. (1996) TIBS 21, 208-214). Some zinc ring finger proteins have been shown to bind to DNA and function as transcriptional repressors (for example, RING 1 ) (Satijn et al. (1997) Mol. Cell. Biol. 17, 4105-4113), whereas others function as transcriptional activators (Chapman and Verma (1996) Nature 382, 678-679;
Monteiro et al.
(1996) Proc. Natl. Acad. Sci. USA 93, 13595-13599). To examine the transcriptional regulatory activity of SAG protein, the cDNA encoding the entire open reading frame of human- SAG was PCR amplified and fused both in frame and as an antisense fusion, downstream of the Gal-4 DNA binding domain (encoding amino acids 1-147) in the pG4 vector (Sadowski et al., Nature 335:563-564, 1988). The resulting construct was sequenced to confirm in frame fusion and freedom from PCR-generated mutation. The construct was co-transfected along with a chloramphenicol acetyltransferase (CAT)-reporter-expressing vector (Sadowski et al., Nature 335:563-564, 1988) as well as a (3-galactosidase reporter whose expression is driven by a CMV promoter for normalization of transfection efficiency into human kidney 293 cells (ATCC accession number CRL1573) by the calcium phosphate method. CAT activity was measured 36 hours post-transfection using a CAT assay kit (Quan-T-CAT; Amersham) according to the manufacturer's instructions. PG4-VP
16, a known transcription factor (Triezenberg et al., Genes and Develop. 2:718-729, 1988), fused doam of the Gal4 DNA binding domain was used as a positive control. Activation was calculated by arbitrarily choosing CAT activity from the vector control as 1 and comparing the other constructs to it. Three independent transfections and assays were performed.
SAG protein showed no transactivation activity. The positive control, VP16 showed 300-fold activation of CAT activity. To test for transrepression activity, SAG
constructs (both sense and antisense) were co-transfected with pG4-VP 16. Again, neither orientation of SAG induced significant expression of VP 16-induced transactivation. These results demonstrated that SAG protein lacks transcriptional regulatory activity when fused downstream Gal-4 DNA binding domain.
Example 12. SAG is an RNA binding protein The zinc-ring finger domain of the MDM2 protein has been shown to bind to RNA
(Elenbaas et al. (1996) Mol. Med. 2, 439-445). Since SAG protein showed no transcriptional regulatory activity, it was tested whether SAG protein could bind to RNA or DNA. Binding of purified SAG protein to different nucleic acid cellulose conjugates was performed as described (Elenbaas et al. (1996)). Briefly, 0.5 wg of SAG protein was incubated in 300 p,L
RNA binding buffer for 1 hour at 4°C with double-stranded calf thymus DNA, denatured calf thymus DNA (ssDNA), or one of 4 RNA homopolymer columns (Sigma) conjugated to agarose or cellulose beads (Sigma), and used according to the manufacturer's instructions.
RNA binding buffer consisted of 20 mM Tris, pH 7.5, 150 mM NaCI, 5 mM MgCl2, 0.1%
nonidet P-40, 50 N,M ZnCl2, 2% glycerol, and 1 mM DTT. The columns were washed with 3 mL RNA binding buffer to remove non-specifically bound protein from the beads, which WO 99/32514 PC"fNS98/26705 were then boiled in SDS sample buffer. The protein so eluted from the beads was separated by SDS-PAGE, transferred to nitrocellulose for Western blot analysis using the polyclonal antibody directed against SAG protein described previously detected by ECL
chemiluminescence (Amersham) according to the manufacturer's instructions.
Purified SAG bound to polyU, polyA, and polyC RNA, respectively. No binding was seen with polyG RNA or ssDNA. A band showing dsDNA binding did not agree with SAG
molecular weigh. Oligomeric SAG protein bound to polyU RNA, whereas the monomeric form of SAG binds to polyA and polyC RNA. Purified SAG protein was run as a marker.
These results suggest that SAG is an RNA binding protein and that binding specificity is determined by the oligomeric form of SAG protein.
Example 13. Identif:cation of two deletion mutants of SAG in cancer cell lines Total RNA was isolated from DLD-1 colon carcinoma cells (ATCC accession number CCL221) and subjected to RT-PCR using primers SAG TA.O1 and SAG T.02. The resulting PCR fragments were subcloned into the TA cloning vector (Invitrogen). During sequence verification of the resulting clones, it was found that several clones contained either a 7 by or a 48 by deletion at nucleotide 170 or 177, respectively, assigning the first A
at the start codon as nucleotide #1. Both SAG deletions encode the potential heme-binding sites.
The 7 base pair deletion (SAG mutant 1) (SEQ ID 11) is a frame shift deletion that abolishes the downstream encoded zinc-ring finger motif in the resulting protein (SEQ ID
12), whereas the 48 base pair deletion (SAG mutant 2) (SEQ ID 13) is an in-frame deletion that eliminates 16 amino acids in the encoded protein (SEQ ID 14), but retains the zinc-ring finger motif.
Total RNA was isolated from a total of 20 human tumor lines and transformed lines originating from lung, brain, kidney, prostate, testis, nasopharynx, bone, cervix and foreskin and subjected to RT-PCR analysis as described previously (Sun et al. (1993) Mol.
Carcinogenesis 8, 49-57). Genomic DNA was also isolated from these cell lines and subjected to PCR amplification as described (Sun et al. (1992) BioTechruques 12:639-640).
The primers used for PCR were hSAG.Ml, 5' GCCATCTGCAGGGTCCAG-3' (SEQ ID IS), starting at nt 151 of hSAG cDNA, and SAGT.02-1 S'-GGATCCTCATTTGCCGATTCTTTGGAC-3' (SEQ ID 16), including stop codon (underlined). The resulting fragment is 200 by for wildtype SAG. The PCR was conducted in the presence of 35S-dATP (Amersham) and PCR products were resolved in 6%
denaturing sequencing gels, as described previously (Sun et al. (1995) Cancer Epidemiology, Biomarkers & Prevention, 4, 261-267). The bands corresponding to wildtype as well as the two deletion mutants were cut out from the gel, PCR amplified using the same set of primers, and sequenced to verify the DNA sequence of the resulting PCR fragments.
Both the 7 base pair and the 48 base pair deletions were detected in RNA from only the CATES-1B cell line, a testicular carcinoma line obtained from ATCC
(accession number HTB 104). This tumor line also contains the wildtype SAG DNA sequence. The identity of these three bands was confirmed by DNA sequencing after PCR amplification and TA
cloning. HONE-1, a nasopharyngeal carcinoma line which only contains wildtype SAG was included for comparison.
It was next examined whether these SAG deletions were detectable at the DNA
level.
Genomic DNA was isolated from CATES-1 B cells and subjected to PCR analysis, as described previously (Sun et aI. (1992) BioTechniques 12:639-640). The primers used were hSAG.Ml and SAG T.02 (see above for sequences). Genomic DNA from CATES-1B
cells possesses only wildtype SAG and no SAG deletion mutants were detected. These results indicate that the SAG deletion mutations occur very rarely in human cancer lines. Detection of the mutations in SAG RNA, but not genomic DNA, may reflect an RNA editing modification of SAG messenger RNA.
Example 14. Production of stable SAG transfected mammalian cells The potential biological function of human SAG protein was examined next by its overexpression in cells. DLD-1 cells were transfected with the following plasmids: the neo control pcDNA-3 (Invitrogen) (identical to pcDNA3.1 described above, except that it lacks the myc-his tag), pcDNA-SAG, pcDNA-SAG-mutant-1, and pcDNA-SAG-mutant-2 (pcDNA3 with SAG, SAG 1 or SAG 2 subcloned into the BamHI site, respectively, using methods well known in the art). The SAG mutant constructs were generated by RT-PCR as follows. Total RNA was isolated from DLD-1 cells, and subjected to reverse transcription, followed by PCR amplification. The primers used were SAG.TA01 (SEQ ID 'n and SAGT.02 (SEQ ID 8), which flank the entire coding region of SAG gene. The PCR
products were digested with restriction enzyme Bam HI, and subcloned into pcDNA3 (In Vitrogen, San Diego), a mammalian expression vector under the transcriptional control of the CMV
promoter, which drives gene expression constitutiveiy. The resultant clones were sequenced to confirm both sense and antisense orientation and freedom of PCR-generated mutations.
DNA sequencing revealed wildtype SAG clone as well as two deletion mutants:
SAG-mutant-1 (7 by deletion, SEQ ID 11 ) and SAG-mutant-2 (48 by deletion, SEQ ID
13) in DLD-1 tumor cells.

DLD-1 cells were transfected by lipofectamine (BRL) with plasmids expressing wildtype (both sense and antisense orientation), SAG mutant-1, and SAG mutant-2, along with the neo control vector. Neomycin resistant colonies were identified by 6418 selection (600 ~,g/mL) for 18 days. Stable clones were ring-isolated by well known methods (Sun et al. (1993) Proc. Natl. Acad. Sci. USA. 90: 2827-2831) and SAG expression was monitored by Northern analysis. Selected clones were examined for SAG protein expression by immunoprecipitation, as described below.
Total RNA was isolated from the cloned cell lines and subjected to Northern analysis.
Cell lines transfected with the following constructs were analyzed: vector controls D 1-3 and D1-6; SAG-wildtype D12-l and D12-8; SAG-mutant-1 D3-3 and D3-4; and SAG-mutant-D4-2 and D4-5.
Northern blot analysis of RNA from selected stable SAG-expressing clones probed with the human SAG cDNA demonstrated that all SAG transfectants express SAG
mRNA, while very low levels of endogenous SAG message were detected in the neo control cells.
The vector control lines and SAG wildtype and SAG deletion mutant transfectants were subsequently subjected to immunoprecipitation using standard techniques (Sun et al.
(1993) Proc. Natl. Acad. Sci. USA. 90: 2827-2831, Sun et al. (1993) Mol.
Carcinogenesis 8, 49-57). Subconfluent SAG transfectants were subjected to methionine starvation for 1 hour and then metabolically labeled with 35S-translabel (0.2 mCi/mL) for 3 hours.
Cells were then lysed on ice for 30 minutes in a lysis buffer comprising 2% Nonidet P40, 0.2% SDS, 0.5% sodium deoxycholate, 1 mM sodium orthovanadate, 5 mM sodium fluoride, 5 mM
sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, and 1 ~,1/mL
leupeptin, and centrifuged at 12,000 x g. The TCA precipitable radioactivity in the supernatant (1 x 108 cpm) was immunoprecipitated using rabbit anti-human SAG antibody (generated as described above). The immunoprecipitates were collected, washed, and analyzed on a 10-20% SDS-polyacrylamide gel, followed by autoradiography. High SAG protein expression was detected only in the wildtype transfectants. The antibody used did not recognize the two SAG protein mutants. These data demonstrate the production of stably transfected cells expressing either wildtype or mutant SAG protein Example 1 S. Morphological appearance of SAG transfectants after exposure to redox reagents Two neo controls (D1-3 and D1-6) and two SAG-producing lines (D12-1 and D12-8) were chosen to examine their sensitivity to redox compounds by morphological observation.
After exposure to 150 p.M OP, 200 p,M H202, or 125 ~,M zinc for 24 hours, the neo-control cells were shrunken and detached, a sign of apoptosis, while SAG-expressing cells appeared morphologically normal. These results indicate that SAG production protects cells from apoptosis induced by redox compounds. Expression of SAG, however, did not offer the protection against copper. No difference in morphological signs of apoptosis was observed with CuS04 treatment (up to 750 ~ between the vector controls and SAG
transfectants.
Higher doses induced apoptosis in all lines.
Example 16. SAG expression protects cells from DNA fragmentation The sensitivity of these SAG-transfected cells to OP-induced apoptosis was examined next by monitoring DNA fragmentation, a hallmark of apoptosis. Subconfluent (80-90%) SAG transfected cells expressing wildtype SAG, SAG mutant-1, SAG mutant-2, or vector control cells, were seeded at 3.5 x 106 per 100 mm dish and exposed after 16-24 hours to 150 lt.M OP, 125 p,M zinc sulfate, or 200 N.M H202 for 24 hours. Both detached and attached cells in 2 x 100 mm dishes were harvested and subjected to DNA fragmentation analysis as follows. Cells were collected by centrifugation and lysed with lysis buffer (5 mM Tris-HCL, pH 8; 20 mM EDTA; 0.5% Triton-X100) on ice for 45 minutes. Fragmented DNA in the supernatant of a 14,000 rpm centrifugation (45 minutes at 4°C) was extracted twice with phenol/chloroform and once with chloroform and precipitated by ethanol and salt. The DNA
pellet was washed once with 70% ethanol and resuspended in TE buffer with 100 ~,g/mL
RNase at 37°C for 2 hours. The fragmented DNA was separated in 1.8%
agarose gel electrophoresis, stained with ethidium bromide, and visualized under ultraviolet light.
OP induced apoptosis in the vector control cells. Less DNA fragmentation was observed in wild type SAG transfected cells compared to control cells. SAG
mutant 1, which does not encode the zinc ring-finger motif, did not show any protection against OP-induced DNA fragmentation, whereas SAG mutant 2, which retains the zinc ring finger domain, still showed protection. These results suggest that overexpression of SAG protein protects cells against OP-induced apoptosis, and the zinc ring finger domain is required for this protective activity.
Since SAG protein contains a zinc ring finger motif, the sensitivity of SAG
transfectants to zinc treatment was examined next. Zinc induced apoptosis in DLD-1 cells WO 99/32514 PCT/US98126~05 transfected with the vector only. Induction of apoptosis was limited by SAG
overexpression, which showed much less DNA fragmentation than the control lines. This data suggests that the SAG protein binds to and chelates zinc through the zinc ring finger domain and thus provides increased resistance to zinc toxicity compared to non-transfected cells.
Another feature of SAG is the formation of oligomers after exposure to H202.
Cells may be protected from H202 induced toxicity by SAG oligomerization. SAG-transfected cells were, therefore, treated with H202 followed by assays for DNA
fragmentation. H202 induced apoptosis in DLD-1 cells. SAG protein overexpression partially protected cells from H202-induced apoptosis, as evidenced by a reduction in DNA fragmentation.
Taken together, these results demonstrate that SAG affords at least some protection against apoptosis induced by redox compounds such as OP and H202 and also against apoptosis caused by zinc.
Example 17. Antisense SAG expression inhibits tumor cell growth To test the growth elects induced by SAG expression, DLD-1 cells were transfected with the neo control vector, or vectors expressing SAG, SAG mutants 1 or 2, or antisense SAG, as described above. Neomycin resistant colonies were selected with 6418 (600 p,g/mL) for 18 days and stained with 50% methanol/10% acetic acid/0.25%
Coomassie Blue.
A stable DLD-1 transfectant expressing antisense SAG mRNA (D15-1) was cloned after 6418 selection in order to examine potential changes in tumor cell phenotype caused by decreased SAG expression. Subconfluent-D15-1 cells, along with the vector control cell (D1-6), and SAG (sense) overexpressing cells (D12-1 and D12-8) were metabolically labeled and subjected to immunoprecipitation using SAG protein antibody as described above.
Densitometric quantitation of SAG protein expression using a computing densitometer, (Molecular Dynamics) was performed according to the manufacturer's instructions. The number was calculated by arbitrarily choosing the value from the vector control cell D1-6 as 1. Antisense SAG transfected cells (D15-1) exhibited a 60% reduction in endogenous SAG protein. Monolayer growth of DLD-1 cells was significantly inhibited by antisense SAG transfection. None of the other transfectants were growth-inhibited, as compared to the neo control.
It was next examined whether antisense SAG-transfected cells would exhibit growth inhibition in soft agar. D15-1 cells, along with transfectants expressing wildtype SAG
(D12-8), SAG mutant-1 (D3-3), SAG mutant-2 (D4-2), as well as the neo control (D1-3) WO 99/32514 PCT/US98l26705 were grown in 0.25% agar medium for 14 days. Colonies containing greater than 16 cells were counted. Three independent experiments, each run in duplicate, were performed.
Shown is the mean +/- standard error of the mean. As shown in Figure 2, down-regulation of SAG in D15-1 cells did cause significant growth inhibition of DLD-I cells as reflected by 75% reduction of soft agar colony number when compared to the neo control (Dl-3), SAG
(sense) expressing line, D12-8, and SAG mutants (D3-3, D4-2).
In a further study, 4 x 106 confluent D15-1 cells along with parental DLD-1 cells, the vector control Dl-6, and ' SAG wildtype transfectant D12-1 cells were inoculated subcutaneously into SCID mice (laconic Farms, Germantown, New York), 10 mice per group. Tumor growth was observed twice a week. The average tumor size/mass for 10 mice was plotted against time post injection up to 24 days. When implanted into SCID mice, antisense expressing line D15-1 failed to form tumors up to 24 days after inoculation, whereas substantial tumor growth was observed in parental DLD-1 cells, the neo control DI-6 cells, and SAG (sense) expressing D12-1 cells (Figure 3). All these experiments demonstrate that downregulation of SAG expression leads to growth inhibition of tumor cells, and further indicates that SAG is a cellular protective molecule.
Example 18. Cancer gene therapy using adenovirus expressing antisense SAG
Since antisense SAG expression has been shown to inhibit tumor growth both in vitro and in vivo (example 1?), SAG can be used as a target for cancer gene therapy.
Methods for conducting cancer gene therapy are well known in the art (see Zhang and Fang, Exp. Opin, Invest. Drugs 4: 487-514, 1995 and Zhang et al., Adv. Pharmacol. 32: 289-341, 1995).
Tumor cell lines with endogenous SAG expression, including, but not limited to DLD-1 (colon), Du145 (prostate), 6401 (kidney), H2009 (lung) and HONET-1 (nasopharynx), are used to establish the tumor models,. Tumor cells from tissue culture are suspended in PBS at a concentration of 5 x 10?/mL and stored on ice. 0.2 mL of the cell suspension (containing approximately ten million cells) is subcutaneously injected into the flank of 6- to 8-week-old athymic nude mice and tumors are allowed to grow for 30-40 days or until the average tumor size reaches 5 mm.
Recombinant adenoviral vectors expressing antisense human SAG, driven by the CMV promoter (Ad.CMV-SAG) were produced by co-transfecting a shuttle plasmid (pJMl7, circularized Ad5 genome) and a recombinant plasmid (pEC-SAG; a CMV driven plasmid containing left arm of Ad5 genome) into 293 cells.

Tumors are injected with either 0.1 mL of recombinant adenoviral solution (1-5 x 1010 pfu/mL) or 0.1 mL of PBS alone as a control. Daily treatment is performed for 2 days and after 1 week without treatment, daily treatment is resumed for 3 days. The tumor size is measured daily for 2 weeks. To test combinatorial therapy with oxygen radical-generating reagents or irradiation, the treated group is subdivided into three sub-groups ( 10 mice per subgroup): group A receives adenovirus alone (see above); group B receives adenovirus and at the same time receives an intraperitoneal injection of adriamycin (3 mg/kg) an oxygen radical-generating reagent, and group C receives adenovirus plus irradiation at 350cGy of cesium-137. Some tumor-bearing mice will only receive the same dose of adriamycin or irradiation as drug or irradiation controls,.
Expression of antisense SAG blocks endogenous SAG synthesis, which renders tumor cells supersensitive to oxygen radicals. Significant tumor shrinkage in treated tumors with or without drugs or radiation, as compared with the vehicle control, indicates the efficacy of this therapy. The tumors in both control and treated groups can be further examined histologically. Samples can be immediately embedded in optimal cutting temperature compound (Miles, Inc. Elkhart, Indiana) and snap-frozen in liquid nitrogen for frozen section preparation (3-5 N,m) for enzymatic staining (e.g., terminal deoxynucleotidyl transferase (Boehringer Manheim, Indianapolis, Indiana) staining for apoptosis) or immunohistochemical staining for expression of the antisense SAG. Alternatively, the samples may be fixed in 10%
formalin for histologic sectioning and analyze with hematoxylin-eosin (Sigma, St. Louis, Missouri) staining.
Example 19. SAG functions as a oxygen radical scavenger to prevent oxygen radical induced damages SAG protein contains 12 cysteine residues and forms disulfide bonds both intermolecularly and intramolecularly after exposure to hydrogen peroxide. SAG
protein also binds to heme, which can modulate oxidants by oxidation/reduction of Fe(++).
This oxidative buffering activity may qualify SAG as an oxygen radical scavenger.
Yeast cells having deletions in antioxidant enzyme genes [superoxide dismutase (SOD) and catalase (CAT)] are supersensitive to superoxide anion and hydrogen peroxide (Longo et al. (1997), J. Cell Biol. 137:1581-1588). Yeast cells that lack (a) Cu, Zn-SOD, (b) Mn-SOD, (c) both Cu, Zn-SOD and Mn-SOD, and (d) CAT have been transfected with human SAG expression plasmids. Sensitivity of these transfected cells to oxygen radical producing compounds such as paraquat (a superoxide anion generating compound) and hydrogen peroxide are tested in yeast growth assays and compared to the growth of the same host cells transfected with vector controls. Rescue of these yeast cells from oxygen radical-induced cell killing indicates that SAG is an effective oxygen radical scavenger.
Example 20. Prevention of IL-1 /3 induced brain injury during ischemia by SAG
administration It has been previously shown that middle cerebral artery occlusion in rats causes overexpression of interleukin-1 which induces brain injury by the release of free radicals (Yang et al., Brain Research 751:181-188, (1997)). Two experiments are conducted to test whether SAG, by scavenging free radicals released, will prevent brain damage.
In the first experiment, human SAG is subcloned into an adenovirus vector driven by RSV promoter (AdRSV-SAG). The adenoviral suspension is injected stereotacdcally into the lateral ventricle to ensure SAG expression in brain. Five days after administration of adenovirus, middle cerebral artery is occluded in animals for 24 hours as described (Yang et al., Brain Research 751:181-188, (1997}). Brain edema (as measured by brain water content) and cerebral infarct size, measured by histological techniques (Yang et al., Stroke 23:1331-1336, (1992)) is determined.. As compared to the vector control, any reduction of brain edema and infarction size indicates SAG protection against free radical induced damage.
In the second experiment, middle cerebral artery occlusion is performed with the rat suture model, allowing either permanent (6 hours) or temporary occlusion (3 hours of occlusion and 3 hours of reperfusion) (Yang and Betz, Stroke, 25:1658-1665, (1994)}. Rats then receive an injection of purified SAG protein at the size of occlusion.
Brain water, ion contents, and infarct volume are measured to determine brain infarction and blood-brain barrier disruption. As compared to injection of the vehicle control, reduction in brain infarction size and blood-brain barrier disruption indicates a SAG protective effect.
Example 21. Human cancer diagnosis using SAG as a marker:
Two SAG deletion mutants in human cancer cell lines originating from colon and testis have been identitifed. Twelve pairs of colon carcinomas and adjacent normal tissues were collected from 12 patients. Genomic DNA and total RNA are isolated from these samples and subjected to PCR amplification. The resulting amplification products are analyzed for detection of SAG deletion mutations by methods well known in the art, including but not limited to RNA protection assays, DNA sequencing, hybridization, and gel electrophoresis for deletion mutants. Mutations detected in tumor tissues but not in normal adjacent tissues indicate that they are tumor specific mutations and can be used as a diagnostic tool in the clinic for colon as well as testicular carcinomas.
Example 22: The yeast homolog of human SAG gene is essential for yeast growth To further understand the function of SAG, yeast SAG knock-out mutants were constructed by homologous recombination. The construct used to knockout yeast SAG was made by PCR of a kanamycin cassette from kanMX4 plasmid (Wach et al., Yeast 10:1793-1808, 1994). The primers used for PCR were SAGKanMX4-5:
5'-TTCTCCAGTGGCAGAGAACTTTAAAGAGAAATAGTTCAAC
CGTACGCTGCAGGTCGAC-3' (SEQ ID 17), and SAGKanMX4-3: 5'-ACCTCGGTA
TGATTTAAATGTTTACGGGCAATTCATTI"'I"T
ATCGATGAATTCGAGCTCG-3' (SEQ ID 18). The primer SAGKanMX4-S consists of yeast SAG DNA sequence (ATCC Accession number 274876) immediately upstream of the initiation codon ATG (underlined) and the upstream kanamycin cassette sequence at its 3'-end. Primer SAGKanMX4-3 consists of yeast SAG DNA sequence immediately downstream of the stop codon TGA (underlined) and the downstream kanamycin cassette sequence at its 3'-end.
PCR was conducted for 5 cycles at 94°C 1 min, 50°C, 1.5 min, 72°C 2 min, followed by 25 cycles at 94°C, 1 min, 56°C, 1.5 min, 72°C 2 min, followed by a 10 min extension at 72°C. The resulting PCR product (1.5 kb) was gel-purified using Qiaex II gel-purification kit (Qiagen) according to the manufacturer's instruction, and was used to transfect the diploid yeast strain Y21 using the YEASTMAKER yeast Transformation System (ClonTech Laboratory, Inc.) according to the manufacturer's instruction. Following transfection, yeast cells were grown in YPD media (Difco) containing 6418 (200 ~.g/mL, BRL) to select transfectants containing the kanamycin cassette, which have had the yeast SAG
deleted by homologous recombination.
Several 6418-resistant clones were selected and assayed to determine whether heterozygous or homozygous deletions had been produced. The primers used are SAGPCR-5: 5'-TTCTCCAGTGGCAGAGAAC-3' (SEQ ID 19) and SAGPCR-3: 5'-ATGATTTAAATGTTTACGGGC-3' (SEQ ID 20). These primers constitute fragments of SAGKanMX4-5 and SAGKanMX4-3, respectively, and flank the entire yeast SAG
coding region. PCR of wildtype yeast SAG produces a 0.35 kb band, whereas PCR of SAG
deletion mutants give rise to I.Skb band, consisting of the kanamycin cassette. Both the 0.35 kb and I.5 kb fragments were generated in all of the clones tested, indicating that heterozygous mutants were produced. Identical knock-out experiments were conducted with haploid yeast cells (InvSC I from In Vitrogen) and no 6418-resistant clone was isolated.
The failure to isolate homozygous yeast SAG deletion mutants suggests that yeast SAG is essential for growth. To confirm this, 12 individual heterozygous yeast strains (y21-ySAG/ySAG::Kan) were sponilated to determine if yeast SAG-kan haploids were viable. The strains were inoculated into minimal potassium acetate sporulation media, supplemented with uracil, lysine, adenine and tryptophan (Kassir, and Simchen, G. Method Enzymol. 194, 94-110, 1991) and grown at 30°C for 7 days. Tetrads was dissected into 4 haploid offspring from each strain. For dissection, a clamp of cells from the sporulation plate was suspended in 100 p.L of 1 M glycerol containing 0.5 mg/mL zymolase T20. After 30 min at 37°C, the suspension was diluted with 800 ~,L sterile water and put on ice. A loop of suspension was struck across a YPD plate and examined under a Zeiss Tetrad microscope for tetrads. The I S glass microneedle of the scope was used to dissect 4 tetrads from each strain. Two of these four haploid cell should contain wildtype SAG, while the other two should contain a yeast SAG deletion. In all 12 clones, only two out of four dissected cell grew, and none were viable in YPD medium supplemented with 6418, indicating that viable cells did not contain the kanamycin cassette or the SAG deletion. The experiment clearly demonstrate that SAG is essential for yeast growth, further demonstrating its evolutionary importance.
To determine if ySAG is required for normal growth or simply for germination, hSAG
was cloned into a yeast expression vector with URA3 selectable marker. The hSAG-URA
plasmid was then transformed into heterozygous ySAG knockout cells, and transformants were selected on URA-minus plates. Clones expressing hSAG (measured by Western blot analysis) were sporulated and tetrads were dissected. Viable colonies were then screened on either YPD alone, or YPD+G418, or YPD+5-fluoroorotic acid (S-FOA; used to select against the UR.A3-containing centromere plasmid (Boeke et aL, Mol. Gen. Genet, 1984;
I97:345).
Again the hSAG-URA3 plasmid complemented the ySAG: : kan allele, as all four haploids from four individual tetrads grew. When grown on YPD+G418 plates, two haploids from each tetrad die, indicating that they contain the wildtype ySAG gene. Other two haploids from each tetrads survived, indicating they contained ySAG: : kan allele. When these latter colonies were grown on YPD+5-FOA plates, which selects against URA3 plasmid, all failed to grow, indicating that ySAG is essential for normal vegetative growth and not simply for sporulation.
Example 23: Human SAG rescue of yeast SAG knockout phenotype To examine whether human SAG can rescue death phenotype of yeast SAG knockout, wildtype human SAG, along with the SAG mutants (MM3, sequence ID 25; MM10, sequence ID 39; and MM14, sequence ID 47, Figure lA) were constructed into a plasmid with Trp selection marker and transfected into heterozygous yeast strain (y21-SAG/ySAG::Kan) as described above. The clones grown in Trp-minus/G4I8-plus plates were examined by Western blot analysis for SAG expression. The clones expressing human SAG were sporulated and dissected. In 10 wildtype human SAG clones, 3 or haploids are viable. Some of them contain yeast SAG, whereas the others contain ySAG K/O
plus human SAG, indicating human wildtype SAG can complement yeast SAG
knockout.
All three mutant clones (total of 41 tested) gave rise to 1 or 2 haploids and all survival haploids contains yeast SAG, indicating that human SAG mutants cannot complement yeast SAG knockout.
Example 24: SAG binds to metals Since SAG contains a zinc-ring finger domain, it has the potential to bind with metals.
To measure potential metal binding of SAG, electrospray ionization mass spectrometry (ESI-MS) (Fenn et al., 1989) was used to compare the molecular mass of SAG
under denaturing and non-denaturing solution conditions (Loo, 1997; Witkowska et al., 1995).
ESI-MS was performed with a double focusing hybrid mass spectrometer (Finnigan MAT 900Q, Bremen, Germany) with a mass-to-charge (m/z) range of 10,000 at 5 kV
full acceleration potential. A position-and-time-resolved-ion-counting (PATRIC) scanning array detector was used. An ESI interface based on a heated metal capillary inlet and a low flow micro-EsI source (150 nL/min analyte flowrate) were used (Sannes-Lowery et al., 1997).
The metal capillary temperature was maintained around 150-200°C for metal-protein complex studies. Recombinant protein under 7 M urea-denaturing solution was refolded by dialyzing in SO ~t.M ZnCl2 for 3 days with three changes of buffer. Prior to ESI-MS
measurement, the SAG solution was washed with a solution of 10 mM ammonium bicarbonate (pH 7) and 1 mM DTT, and excess zinc was removed by centrifugal ultrafiltration by passing through a 10 kDa molecular weight cut-off centrifugal filtration cartridge (Microcon-10 microconcentrator, Amicon, Beverly, MA). For the ESI-MS

WO 99/32514 PCTNS981~6705 analysis, a small portion of the filtered SAG protein solution was diluted into either a denaturing solvent (80:15:5 acetonitrile:water:acetic acid v/v/v, pH 2.5) or a non-denaturing solution (10 mM ammonium bicarbonate and 1 mM DTT, pH 7).
Zinc binding of SAG was first measured. Under a denaturing acidic solution (pH
2.5 and high organic concentration) where the protein is not expected to retain metal-binding characteristics even in the presence of zinc, the molecular mass of SAG was measured to be 12550, in close agreement with the expected mass for the apo-protein (12552 Da). The ESI-MS analysis of the SAG protein in a non-denaturing aqueous solution (pH 7) resulted in an increase in mass to 12733 and 12800 Da. These masses are consistent for the holo-protein binding 3 and 4 zinc metal ions, respectively.
Copper binding to SAG was also measured. As little as 1 N,M CuS04 in the dialysis solution causes SAG precipitation with a blue (copper) color, suggesting a copper binding.
Next, using ESI-MS, the potential copper binding of SAG was measured in a non-denaturing solution described above. Addition of copper acetate to a final concentration of 10 ~,M
resulted in a further inccrease in mass to approximately 12929 Da. However, a precise mass could not be obtained, as a wide distribution of copper adducts appears to bind to SAG
pmtein. Adding copper to higher concentrations resulted in precipitation of the protein.
Example 2S: SAG minimizes or prevents LDL oxidation induced by copper ion or a free radical generator Due to its H202 buffering and metal binding, it was reasoned that SAG may prevent oxidation of macromolecules induced by metal or free radical generator. An LDL
(low density lipoprotein) oxidation induced by copper ion or a free radical generator, AAPH (2,2-azobis-2-amidinopropane hydrochloride), was used as a model to test potential protection activity of SAG against lipid peroxidation.
Lipoproteins (100 ~,g of protein/mL, Intraocel) were incubated with 10 ~t.M
CuS04 or with 5 mM AAPH for 4 hours at 37°C in the presence of various concentrations of purified SAG protein. AAPH is a water-soluble azo compound that thermally decomposes and generates water soluble peroxyl radicals at a constant rate (Frei et al., 1988). Oxidation was terminated by the addition of 10 ~.M butylated hydrozytoluence (BHT) and refrigeration at 4°C. The extent of lipoprotein oxidation was measured by the TBARS
assay, using malondialdehyde (MDA) for the standard curve, as described (Buege & Aust, 1978).

Copper-induced LDL oxidation, as measured by the formation of thio barbituric acid reactive substances (TBARS), was slightly enhanced by SAG at low concentrations. At higher SAG concentrations, however, a dose-dependent inhibition (up to 90%) of LDL
oxidation was observed. Inhibition was heat-resistant since heat-treated (60°C for 1 S min) SAG still retains the activity, suggesting that enzymatic activity is not involved. Inhibitory activity was, however, completely or partially abolished by pretreatment of SAG with alkylating reagents NEM and p-hydroxy mercury benzoate (PHMB), respectively.
The results indicated that free SH groups in SAG are the major contributors to this activity.
Furthermore, metallothionein, a small metal binding protein consisting of 20 cysteine residues out of 61 amino acids (Nordberg & Kojima, 1979) showed a similar inhibitory curve as SAG. Glutathion (GSH), an additional cysteine containing peptide showed a 25%
inhibition at a concentration of 100 ~.M. Inhibition of copper-induced LDL
oxidation was;
however, not observed in other known antioxidant enzymes such as superoxide dismutase, catalase or other proteins such as BSA, and cytochrome C. These results clearly showed that 1 S by binding and chelating copper ion through its free SH groups, SAG
prevents copper-initiated free radical reactions leading to LDL oxidation and superoxide or hydrogen peroxide appear not to be involved in the process. To test whether SAG protection against LDL
oxidation was solely mediated through copper binding, we initiated LDL
oxidation by AAPH, a free radical generator. In this metal-ion free system, SAG also protects LDL
oxidation (up to 85%) at a concentration of 59 p,M (750 p,g/mL). Thus, by metal binding and free radical scavenging, SAG acts as a protector against lipid peroxidation.
Example 26. SAG protects cytochrome C release and caspase activation induced by metal ions Since cytochrome C release from mitochondria and caspase activation are the key events in apoptosis (Liu et al., 1996; Yang et al.; 1997; Li et al., 1997;
Hengartner, 1998, for review, see Mignotte & Vayssiere, 1998), the levels of cytochrome C released into cytoplasm and potential activation of caspase upon metal treatments were measured.
Treatment of cells with ZnS04 induces a time-dependent release of cytochrome C in cytoplasm.
Compared to the vector control cell (D 1-6), the SAG overexpressing cell (D 12-1 ) has much less cytoplasmic release of cytochrome C. Likewise, activation of caspase 7, shown as disappearance of pro-enzyme form, was seen in a time-dependent manner post zinc treatment.
More activation was seen in vector control cell (D1-6) than that in the SAG
overexpressing cell (D12-1). A similar result was obtained with CPP32 (caspase 3) activation.
A significant difference, however, was not seen in cytochrome C release or caspase activation between D1-6 and D12-1 cells upon copper treatment. This is consistent with the lack of difference in morphological changes between the two lines upon copper treatment, although DNA
fragmentation was obvious only in the vector control cells. To further examine potential protection of SAG against metal-induced cytochrome C release and CPP32 activation, cytochrome C release and CPP32 activation was measured in 293 cells transiently transfected with SAG expressing plasmid followed by exposure to copper. A significant amount of cytochrome C started to release 6 hours post CuS04 (2.0 mM) treatment and lasted up to 12 hours. Expression of SAG delayed cytochrome C release for up to 16 hours.
Activation of caspase 7 was seen in the vector control cells 12 hours and 16 hours post copper treatment.
No significant activation was seen in SAG transfectants. The similar result was seen with CPP32 antibody. For zinc treatment, no difference was detected in cytochrome C
release and caspase activation between control cells and SAG transfectants, consistent with the lack of difference in morphological signs of apoptosis. These results indicate that metal treatment induces cytochrome C release and caspase activation during apoptosis which can be largely prevented or delayed by SAG and there is a good correlation between morphological signs of apoptosis and cytochrome C release/caspase activation.
Example 27: SAG protects against neuronal apoptosis SAG was transfected into HYSY human neuroblastoma cells and a few stable lines were selected which expressed exogenous SAG as determined by Western blot. One SAG-transfectant (SYW-20) and a vector control (SYV-3) were used to determine their sensitivity to metal ions, zinc and copper. Treatment with 1.25 mM CuS04 or 200 ~tM ZnS04 for 16 hours induced cell shrinkage and detachment in the neo control cells, but to a less extent in SAG-expressing cells. The morphological difference was more obviously seen with the zinc treatment. To determine the nature of cell death, we performed TLJNEL assay, a fluorescein labelling assay of free 3'-OH termini generated from cleavage of genomic DNA
during apoptosis.
In Situ cell death assay (TLJNEL assay) was performed according to the manufactwer's instructions (Boehringer Mannheim). Briefly, 5 x 104 cells were plated into the 8-well glass slides. After treatment with 1.25 mM copper (CuS04) or 200 ~,M zinc (ZnS04) for 16 hours, cells were fixed with 0.5% glutaraldehyde for 10 min, then washed with PBS twice. The fixed cells were incubated in permeabilization solution (0.1 % Triton X-100, 0.1 % sodium citrate) for 2 min on ice. The TUNEL reaction mixture (50 ~.L) was added to samples and incubated for 1 hour at 37°C followed by 3 times wash with PBS.
Samples were embedded with antifade prior to analysis under a fluorescence microscope.
Substantially more fluorescein staining was seen in the vector control cells after 16 hours treatment with 1.25 mM CuS04, or 200 ~M ZnS04. The results indicate that expression of SAG protects neuronal cells from apoptosis.
Example 28. SAG stimulates proliferation To test potential growth stimulation activity, SAG RNA (8 ~.g/mL or 25 ~.g/mL), along with the control ~-galactosidase (25 ~g/mL), was injected into serum-starved NIH 3T3 fibroblast monolayer. Approximately 50 cells attached to the glass coverslip within an etched circle were injected. A 3-hour pulse of [3H]thymidine (5 ~,Ci/mL, Amersham) was performed 10 to 24 hours after injection. Cultures were washed with isotonic phosphate-buffered saline and fixed in 3.7% (vo11vo1) formaldehyde. Induction of [3H]thymidine incorporation (an indicator of DNA synthesis) into the nuclei of serum-starved fibroblast cells was obviously observed in SAG-injected cells. In contrast, injection of ~-galactosidase does not induce DNA synthesis and no [3H]thymidine incorporation was observed. The results clearly indicate that human SAG has proliferative activity to stimulate cell growth.
Growth promotion activity of SAG was also examined in human neuroblastoma cells (SYSY), overexpressing hSAG protein by hSAG cDNA transfection. Both the vector-expressing control cells and SAG overexpressing cells were first serum-starved for 48 hours, followed by 3H-thymidine labelling for 16 hours in either serum-starved or 1 %
serum conditions. Cells were washed, lysed and counted in a liquid scintillation counter for 3H, an assay for the measurement of 3H-thymidine incorporation into DNA (S-phase entry).
Compared to the vector control cells, SAG-expressing cells have 10-fold more 3H-thymidine incorporation in both conditions (serum-free or 1 % serum), indicating that SAG stimulates cell proliferationlgrowth.
Growth promotion activity of SAG was also examined in yeast. As described in Example 22, the yeast homolog of human SAG gene is essential for yeast growth.
To correlate yeast growth rate with SAG expression, hSAG expressing plasmid was constructed under control of Gal promoter. The plasmid was transformed into heterozygous ySAG
knockout and transformants were sporulated and dissected. Haploid ySAG
knockout clone that contained hSAG plasmid was identified and analyzed. In the uninduced condition, little SAG expression due to the leakness of the promoter led to formation a tiny clone compared to the full size wildtype clone. Under induced condition, SAG expression level increased and clone size also increased. This experiment clearly demonstrated that SAG
promotes cell growth in a dose-dependent manner.
It is to be understood that the invention is not to be limited to the exact details of operation, or to the exact compounds, compositions, methods, procedures or embodiments shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art, and the invention is therefore to be limited only by the full scope of the appended claims.

SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Yi Sun (B) STREET: 4841 Hillway Court (C) CITY: Ann Arbor (D) STATE: Michigan (E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 48105 (G) TELEPHONE: (313) 996-1959 (H) TELEFAX: (313) 996-7158 (ii) TITLE OF INVENTION: Sensitive to Apoptosis Gene (SAG) (iii) NUMBER OF SEQUENCES: 50 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID N0: l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1140 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/ICEY: CDS
(B) LOCATION:17.:355 (ix) FEATURE:
(A) NAME/KEY: mat_peptide (B) LOCATION:17..355 (ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION:1..1140 (D) OTHER INFORMATION:/note= "Mouse SAG"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 1:

Met Ala Asp Val Glu Asp Gly Glu Glu Pro Cys Val Leu Ser Ser His Ser Gly Ser Ala Gly Ser Lys Ser Gly Gly Asp ATG AAC ATG

LysMet PheSerLeu LysLysTrp AlaVal Ala Trp SerTrp Asn Met ATC CAG

AspVal GluCysAsp ThrCysAla CysArg Val Val MetAsp Ile Gln AAC GAC

AlaCys LeuArgCys GlnAlaGlu LysGln Glu Cys ValVal Asn Asp 60 65 ?0 75 TTC TGC

ValTrp GlyGluCys AsnHisSer HisAsn Cys Met SerLeu Phe Cys CCT CAG

TrpVal LysGlnAsn AsnArgCys LeuCys Gln Asp TrpVal Pro Gln CCCAGGCGCT
CCTGGTGTGG

ValGln ArgIleGly Lys (2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

WO 99/32514 PCT/ITS98~6705 Met Ala Asp Val Glu Asp Gly Glu Glu Pro Cys Val Leu Ser Ser His Ser Gly Ser Ala Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln~Glu Asp Cys Val Val Val Trp Gly Glu Cys 65 70 ~ 75 80 Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/REY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat-peptide (B) LOCATION:1..339 .
(ix) FEATURE:
(A) NAME/KEY: misc_feature (B) LOCATION:1..754 (D) OTHER INFORMATION:/note= "Human SAG"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 3:

Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys GCT AAC CAA TGT GTG GAA
GAG

GlnAla GluAsnLys GluAsp ValVal ValTrp Gly Cys Gln Cys Glu AAC ATG CAG

AsnHis SerPheHis CysCys'MetSerLeu TrpVal Lys Asn Asn Gln TGC GAC ATC

AsnArg CysProLeu GlnGln TrpVal ValGln Arg Gly Cys Asp Ile TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys (2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 4:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide P1 downstream primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

(2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide: P2 upstream primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

(2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "Oligonucleotide SAG TA. O1"
S

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

(2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide SAG T.02"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

(2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide P.01"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 9:

(2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 10:
Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg (2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 747 base pairs (B} TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/REY: CDS
(B) LOCATION:1..270 (ix) FEATURE:
(A) NAME/KEY: mat~eptide (B) LOCATION:1..270 (xi} SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GCC GGA GAG ACC CTG

Met AspValGlu Asp Glu Glu Cys Ala AlaSerHis Ala Gly Thr Leu GGG AAG GGC ATG

Ser SerSerGly Ser Ser Gly Asp Lys PheSerLeu Gly Lys Gly Met AAG GCC AGC GTG

Lys TrpAsnAla Val Met Trp Trp Asp GluCysAsp Lys Ala Ser Val TGC GTC CCT GAT

Thr AlaIleCys Arg Gln Met Val Leu ValLysLeu Cys Val Pro Asp ACA GTG TCT AAT

Lys AsnLysArg Thr Leu Trp Gly Glu ValIleIle Thr Val Ser Asn TCC TGT GGG CAATCGCTGC

Pro ThrThrAla Ala Pro Cys Ser Cys Gly 7.

(2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 90 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Met Pro Val Leu Asp Val Lys Leu Lys Thr Asn Lys Arg Thr Val Leu Trp Ser Gly Glu Asn Val Ile Ile Pro Ser Thr Thr Ala Ala Cys Pro Cys Gly (2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 706 base pairs , (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..291 (ix} FEATURE:
(A) NAME/KEY: mat~eptide (B) LOCATION:1..291 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GAG CTG

MetAla Asp Val Glu Asp Gly Glu Thr Cys Ala AlaSerHis Glu Leu TCG ATG

SerGly Ser Ser Gly Ser Lys Gly Gly Asp Lys PheSerLeu Ser Met g WO 99/32514 PCT/US98n6705 AAC GTG TGG TGC
AGC

LysLysTrp Ala Ala Met Ser TrpAspVal Glu Asp Asn Val Trp Cys ATC AGG GTG GAA

ThrCysAla Cys Val Gln Met ValValTrp Gly Cys Ile Arg Val Glu TTC AAC ATG CAG

AsnHisSer His Cys Cys Ser LeuTrpVal Lys Asn Phe Asn Met Gln CCT TGC GAC ATC

AsnArgCys Leu Gln Gln Trp ValValGln Arg Gly Pro Cys Asp Ile TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys (2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 97 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2} INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide hSAG. Ml"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

(2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide SAG T.02L"
(xi} SEQUENCE DESCRIPTION: SEQ ID NO: 16:

(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide SAGKanMX4-5"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

1~

(2) INFORMATION FOR SEQ ID N0: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 59 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide SAGKan MX
4-3"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

(2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide SAG pcr 5"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

(2) INFORMATION FOR SEQ ID N0: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "oligonucleotide SAG pcr 3"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

(2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:1..339 (ix) FEATURE:

(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GAC GAC GAG ACC TCT

Met Ala Val Glu Gly Glu Cys AlaLeuAla His Asp Asp Glu Thr Ser AGC TCC TCG GGC TCC

Ser Gly Ser Gly Lys Gly Asp LysMetPhe Leu Ser Ser Ser Gly Ser TGG GTG ATG AGC TGC

Lys Lys Asn Ala Ala Trp Trp AspValGlu Asp Trp Val Met Ser Cys GCC AGG CAG ATG AGA

Thr Ser Ile Cys Val Val Asp AlaCysLeu Cys Ala Arg Gln Met Arg GAA CAA GAC GTT GAA

Gln Ala Asn Lys Glu Cys Val VaITrpGly Cys GIu Gln Asp Val Glu TCC AAC TGC TCC CAG

Asn His Phe His Cys Met Leu TrpValLys Asn Ser Asn Cys Ser Gln TGC TGC CAG TGG ATC

Asn Arg Pro Leu Gln Asp Val ValGlnArg Gly Cys Cys Gln Trp Ile TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys (2) INFORMATION FOR SEQ ID NO': 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Ser Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn g5 90 95 Asr~ Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS

(B) LOCATION:1..339 (ix) FEATURE:

(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His GGG GGC TCG GGC TCC

Ser Ser Ser Ser Lys Gly Asp LysMet Phe Leu Gly Gly Ser Gly Ser AAG GCG ATG AGC TGC

Lys Trp Asn Val Ala Trp Trp AspVal Glu Asp Lys Ala Met Ser Cys TGC AGC CAG ATG AGA

Thr Ala Ile Arg Val Val Asp AlaCys Leu Cys Cys Ser Gln Met Arg GCT AAA GAC GTT GAA

Gln Glu Asn Gln Glu Cys Val ValTrp Gly Cys Ala Lys Asp Val Glu CAT CAC TGC TCC CAG

Asn Ser Phe Asn Cys Met Leu TrpVal Lys Asn His His Cys Ser Gln CGC CTC CAG TGG ATC

Asn Cys Pro Cys Gln Asp Val ValGln Arg Gly Arg Leu Gln Trp Ile TGAGAGTGGT
TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys Z"r~ 7 (2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Ser Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS

(B) LOCATION:1..339 (ix) FEATURE:

(A) NAME/KEY: mat_peptide (B) LOCATION:1..339 (xi) SEQUENCE
DESCRIPTION:
SEQ ID NO:
25:

GTG GAG ACC GCC TCT

Met AIa Asp GluAsp Gly Glu Cys LeuAla His Val Glu Thr Ala Ser TCA TCG GGC AAG TCC

Ser Gly Ser GlySer Lys Gly Asp MetPhe Leu Ser Ser Gly Lys Ser AAC ATG AGC GAC TGC

Lys Lys Trp AlaVal Ala Trp Trp Va1Glu Asp Asn Met Ser Asp Cys ATC CAG ATG GCC AGA

Thr Ser Ala SerArg Val Val Asp CysLeu Cys Ile Gln Met Ala Arg AAC GAC GTT GTC GAA

Gln Ala Glu LysGln Glu Cys Val TrpGly Cys Asn Asp Val Val Glu TTC TGC TCC TGG CAG

IS

Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Ser Ala Ile Ser Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID N0: 27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat_peptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

GTG TGC GCC TCT

Met AlaAsp Glu Asp Gly Glu Glu Thr Leu Ala His Val Cys Ala Ser TCA GAC AAG TCC

Ser GlySer Gly Ser Lys Ser Gly Gly Met Phe Leu Ser Asp Lys Ser AAC TGG GAC TGC

Lys LysTrp Ala Val Ala Met Trp Ser Val Glu Asp Asn Trp Asp Cys ATC GAT GCC AGA

Thr CysAla Cys Arg Val Gln Val Met Ser Leu Cys Ile Asp Ala Arg AAC GTG GTC GAA

Gln AlaGlu Lys Gln Glu Asp Cys Val Trp Gly Cys Asn Val Val Glu TTC CTG TGG CAG

Asn HisSer His Asn Cys Cys Met Ser Val Lys Asn Phe Leu Trp Gln CCT GTG GTC ATC

Asn ArgCys Leu Cys Gln Gln Asp Trp Gln Arg Gly Pro Val Val Ile TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys WO 99/32514 ~ PCT/US98/Z6705 I"r~ 7 5 4 (2) INFORMATION FOR SEQ ID N0: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Ser Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID N0: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS

(B) LOCATION:1..339 (ix) FEATURE:

(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 Ig (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu AAG AAC GCC TGG
AGC
TGG
GAC

LysLysTrp Ala Val Met Ser Trp Val Glu Cys Asp Asn Ala Trp Asp ATC GTC GTG GCC

ThrCysAla Cys Arg Gln Met Asp Cys Leu Arg Cys Ile Val Val Ala AAC GAG TGT GTC

GlnAlaGlu Lys Gln Asp Val Val Trp Gly Glu Ser Asn Glu Cys Val TTC TGC ATG TGG

AsnHisSer His Asn Cys Ser Leu Val Lys Gln Asn Phe Cys Met Trp CCT CAG GAC GTC

AsnArgCys Leu Cys Gln Trp Val Gln Arg Ile Gly Pro Gln Asp Val TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys (2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Ser Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID N0: 31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat-peptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION:
SEQ ID NO: 31:

GCC GGA ACC GCC

~Iet Asp Val Glu Asp Glu Glu Cys Leu AlaSerHis Ala Gly Thr Ala GGG AAG GGC AAG

Ser Ser Ser Gly Ser Ser Gly Asp Met PheSerLeu Gly Lys Gly Lys AAG GCC AGC GAC

Lys Trp Asn Ala Val Met Trp Trp Val GluCysAsp Lys Ala Ser Asp TGC GTC ATG GCC

Thr Ala Ile Cys Arg Gln Val Asp Cys LeuArgCys Cys Val Met Ala GCT GAG GTT GTC

Gln Glu Gln Glu CysVal ValVal Trp Gly Cys Ala Asn Asp Glu Lys AAA TTC TGC CAG

Asn Ser HisAsn Cys MetSer LeuTrp Val Lys Asn Lys Phe Cys Gln AAT TGC CTCTGC CAG GACTGG GTGGTC CAA AGA GGC . 336 CGC CCT CAG ATC

Asn Cys LeuCys Gln AspTrp ValVal Gln Arg Gly Arg Pro Gln Ile TGAGAGTGGT
TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG
CCCTGGTGGA

Lys (2) INFORMATION FOR SEQ ID NO: 32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn Lys Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 33:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

GAC GAC GAA TCT
CAC

MetAla Val Glu Gly Glu ThrCysAla LeuAla His Asp Asp Glu Ser AGC TCC GGA TCC

SerGly Ser Gly Lys Ser GlyAspLys MetPhe Leu Ser Ser Gly Ser TGG GTG TGG TGC

LysLys Asn Ala Ala Met SerTrpAsp ValGlu Asp Trp Val Trp Cys GCC AGG GTG AGA

ThrCys Ile Cys Val Gln MetAspAla CysLeu Cys Ala Arg Val Arg GAA CAA TGT GAA

GlnAla Asn Lys Glu Asp ValValVal TrpGly Cys Glu Gln Cys Glu TCC AAC ATG CAG

AsnHis Phe Lys Cys Cys SerLeuTrp ValLys Asn Ser Asn Met Gln TGC TGC GAC ATC

AsnArg Pro Leu Gln Gln TrpValVal GlnArg Gly Cys Cys Asp Ile TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys CAGTGCCCTA CTTCAAATAG
CAAAGGCTAG
AACACTACAG

Z'T~ 754 (2) INFORMATION FOR SEQ ID NO: 34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe Lys Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:

(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:
ATG GCC GAC GTG. GAA GAC GGA GAG GAA ACC TGC GCC CTG GCC TCT CAC 48 Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp GCC CAG ATG AGA
GAT

ThrCys IleCysArg Val Val MetAspAla Cys Leu Cys Ala Gln Arg GAA GAC GAA

GlnAla AsnLysGln Glu Cys ValValVal Trp Gly Cys Glu Asp Glu TCC AGC CAG

AsnHis PheHisAsn Cys Met SerLeuTrp Val Lys Asn Ser Ser Gln TGC CAG ATC

AsnArg ProLeuCys Gln Asp TrpValVal Gln Arg Gly Cys Gln Ile TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys (2} INFORMATION FOR SEQ ID N0: 36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Ser Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/REY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys GAA TGT GAA

GlnAla AsnLys GlnGluAsp ValVal ValTrp Gly Cys Glu Cys Glu TCC ATG CAG

AsnHis PheHis AsnCysCys SerLeu TrpVal Lys Asn Ser Met Gln AGC GAC ATC

AsnArg ProLeu CysGlnGln TrpVal ValGln Arg Gly Ser Asp Ile AAATGAGAGTGGT CCCTGGTGGA 3$9 TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys (2) INFORMATION FOR SEQ ID NO: 38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 38:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Ser Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat_peptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION:
SEQ ID NO: 39:

GCC GGA ACC GCC TCT

Met Asp Val Glu Asp Glu Glu Cys Leu Ala His Ala Gly Thr Ala Ser GGG AAG GGC AAG TCC

Ser Ser Ser Gly Ser Ser Gly Asp Met Phe Leu Gly Lys Gly Lys Ser AAG GCC AGC GAC TGC

Lys Trp Asn Ala Val Met Trp Trp Val Glu Asp Lys Ala Ser Asp Cys TGC GTC ATG GCC AGA

Thr Ala Ile Cys Arg Gln Val Asp Cys Leu Cys Cys Val Met Ala Arg GCT GAG GTT GTC GAA

Gln Glu Asn Lys Gln Asp Cys Val Trp Gly Cys Ala Glu Val Val Glu AAA TGC TCC TGG CAG

Asn Ser Phe Lys Asn Cys Met Leu Val Lys Asn Lys Cys Ser Trp Gln CGC CAG TGG GTC ATC

Asn Cys Pro Leu Cys Gln Asp Val Gln Arg Gly Arg Gln Trp Val Ile TGAGAGTGGT
TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys i I

CTTCAAATAG

TGTCAGTTTT

TTCCTACCTC

GCTCCAAATT

TTCGAGACTT

AAAGTGCAGT

(2) INFORMATION FOR SEQ ID N0: 40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 40:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn Lys Ser Phe Lys Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 41:

Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu AAC GTG TGG AGC TGC
TGG GAC

LysLysTrp AsnAlaVal Ala Met Ser AspValGlu Asp Trp Trp Cys GTG GAT AGA

ThrCysAla IleCysArg Val Gln Met AlaCysLeu Ser Val Asp Arg TGT GTG GAA

GlnAlaGlu AsnLysGln Glu Asp Val ValTrpGly Cys Cys Val Glu ATG CTG CAG

AsnHisSer PheHisAsn ~Cys Cys Ser TrpValLys Asn Met Leu Gln GAC GTG ATC

AsnArgCys ProLeuCys Gln Gln Trp ValGlnArg Gly Asp Val Ile TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys (2) INFORMATION FOR SEQ ID NO: 42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Ser Gln Ala Glu Asn Lys Gln Glu Asp Gys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION F'OR SEQ ID N0: 43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys AsnAla Ala TrpSerTrp AspVal Glu Asp Trp Val Met Cys GCC AGG CAG AGA

Thr Cys IleCys Val ValMetAsp AlaCys Leu Cys Ala Arg Gln Arg GAA CAA GAC GAA

Gln Ala AsnLys Glu SerValVal ValTrp Gly Cys Glu Gln Asp Glu TCC AAC TGC CAG

Asn His PheHis Cys MetSerLeu TrpVal Lys Asn Ser Asn Cys Gln TGC TGC CAG ATC

Asn Arg ProLeu Gln AspTrpVal ValGln Arg Gly Cys Cys Gln Ile TAGAAGGCTT
CTTAGCGCAG
TTGTTCAGAG

Lys (2) INFORMATION FOR SEQ ID NO: 44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln VaI Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Ser Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

GCC GAA GAA CAC
GAC GAC

MetAla Val Glu Gly Glu Thr CysAIaLeu AlaSerHis Asp Asp Glu AGC TCC GGA

SerGly Ser Gly Lys Ser Gly AspLysMet PheSerLeu Ser Ser Gly TGG GTG TGG

LysLys Asn Ala Ala Met Ser TrpAspVal GluCysAsp Trp Val Trp GCC AGG GTG

ThrCys Ile Cys Val Gln Met AspAlaSer LeuArgSer Ala Arg Val GAA CAA TGT

GlnAla Asn Lys Glu Asp Val ValValTrp GlyGluCys Glu Gln Cys TCC AAC ATG

AsnHis Phe His Cys Cys Ser LeuTrpVal LysGlnAsn Ser Asn Met TGC TGC GAC

AsnArg Pro Leu Gln Gln Trp ValValGln ArgIleGly Cys Cys Asp Lys TTTCGATGCT TATGGTTGAT CAGTTA.AAAA AGAATGTTAC AGTAACAAAT AAAGTGCAGT 749 (2) INFORMATION FOR SEQ ID NO: 46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Ser Leu Arg Ser Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Ser Pro Leu Ser Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE bESCRIPTION: SEQ ID NO: 48:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Cys Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Ser Pro Leu Ser Gln Gln Asp Trp Val VaI Gln Arg Ile Gly Lys (2) INFORMATION FOR SEQ ID NO: 49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 754 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1..339 (ix) FEATURE:
(A) NAME/KEY: mat~eptide (B) LOCATION:1..339 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His AGC GGC GGC ATG TCC

SerGly SerSerGly SerLysSerGly GlyAsp LysMetPhe Leu Ser AGC

LysLys TrpAsnAla ValAlaMetTrp SerTrp AspValGlu Asp Ser AGA

ThrCys AlaIleCys ArgValGlnVal MetAsp AlaCysLeu Cys Arg GAA

GlnAla GluAsnLys GlnGluAspCys ValVal ValTrpGly Cys' Glu CAG

AsnHis SerPheHis AsnCysCysMet SerLeu TrpValLys Asn Gln ATC

AsnArg CysProLeu CysGlnGlnAsp TrpVal ValGlnArg Gly Ile Lys (2) INFORMATION FOR SEQ ID NO: 50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 113 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:
Met Ala Asp Val Glu Asp Gly Glu Glu Thr Cys Ala Leu Ala Ser His Ser Gly Ser Ser Gly Ser Lys Ser Gly Gly Asp Lys Met Phe Ser Leu Lys Lys Trp Asn Ala Val Ala Met Trp Ser Trp Asp Val Glu Ser Asp Thr Cys Ala Ile Cys Arg Val Gln Val Met Asp Ala Cys Leu Arg Cys Gln Ala Glu Asn Lys Gln Glu Asp Cys Val Val Val Trp Gly Glu Cys Asn His Ser Phe His Asn Cys Cys Met Ser Leu Trp Val Lys Gln Asn Asn Arg Cys Pro Leu Cys Gln Gln Asp Trp Val Val Gln Arg Ile Gly Lys

Claims (37)

I claim

1. An isolated and purified DNA sequence substantially similar to the DNA
sequence shown in SEQ ID 1.

2. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID 1 under high stringency hybridization conditions.

3. An isolated and purified DNA sequence that consists essentially of the DNA
sequence shown in SEQ ID 1.

4. A recombinant DNA molecule comprising the isolated and purified DNA
sequence of Claim 1, 2, or 3 subcloned into an extra-chromosomal vector.

5. A recombinant host cell comprising a host cell transfected with the recombinant DNA
molecule of Claim 4.

6. A recombinant host cell deposited with the ATCC under accession number 98402.

7. An isolated and purified DNA sequence substantially similar to the DNA
sequence shown in SEQ ID 3.

8. An isolated and purified DNA sequence that hybridizes to the DNA sequence shown in SEQ ID 3 under high stringency hybridization conditions.

9. An isolated and purified DNA sequence that consists essentially of the DNA
sequence shown in SEQ ID 3.

10. A recombinant DNA molecule comprising the isolated and purified DNA
sequence of Claim 7, 8, or 9 subcloned into an extra-chromosomal vector.

11. A recombinant host cell comprising a host cell transfected with the recombinant DNA
molecule of Claim 10.

12. A recombinant host cell deposited with the ATCC under accession number 98403.

13. A recombinant host cell deposited with the ATCC under accession number 98404.

14. A recombinant host cell deposited with the ATCC under accession number 98405.

15. An isolated and purified DNA sequence selected from the group consisting of SEQ
ID 11, SEQ ID 13, SEQ ID 21, SEQ ID 23, SEQ ID 25, SEQ ID 27, SEQ ID 29, SEQ
ID 31, SEQ ID 33, SEQ ID 35, SEQ ID 37, SEQ ID 39, SEQ ID 41, SEQ ID 43, SEQ ID 45, SEQ
ID 47, and SEQ ID 49.

16. A recombinant DNA molecule comprising an isolated and purified DNA
sequence of Claim 15, subcloned into an extra-chromosomal vector.

17. A recombinant host cell comprising a host cell transfected with a recombinant DNA
molecule of Claim 16.

18. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID 2.

19. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially of the amino acid sequence shown in SEQ ID 2.

20. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide is substantially similar to the amino acid sequence shown in SEQ ID 4.

21. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the substantially purified recombinant polypeptide consists essentially of the amino acid sequence shown in SEQ ID 4:

22. A substantially purified recombinant polypeptide, wherein the amino acid sequence of the polypeptide is selected firm the group consisting of SEQ ID 12, SEQ ID 14, SEQ ID 22, SEQ ID 24, SEQ ID 26, SEQ ID 28, SEQ ID 30, SEQ ID 32, SEQ ID 34, SEQ ID 36, SEQ
ID 38, SEQ ID 40, SEQ ID 42, SEQ ID 44, SEQ ID 46, SEQ ID 48, and SEQ ID 50.

23. An antibody that selectively binds polypeptides with an amino acid sequence substantially similar to the amino acid sequence of Claim 18, 19, 20, 21 or 22.

24. A method of detecting SAG protein in cells, comprising contacting cells with the antibody of Claim 23 and incubating the cells in a manner that allows for detection of the SAG protein-antibody complex.

25. A diagnostic assay for detecting cells containing SAG mutations, comprising isolating total genomic DNA from the cell and subjecting the genomic DNA to PCR
amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, 3, 7, 8, 9, or 15, and determining whether the resulting PCR product contains a mutation.

26. A diagnostic assay for detecting cells containing SAG mutations, comprising isolating total cell RNA, subjecting the RNA to reverse transcription-PCR amplification using primers derived from the isolated and purified DNA sequence of Claim 1, 2, 3, 7, 8, 9, or 15 and determining whether the resulting PCR product contains a mutation.

27. A method of isolating RNA containing stretches of polyA or polyC residues, comprising (a) contacting an RNA sample with SAG protein in RNA binding buffer in the presence of a reducing agent;
(b) incubating the RNA-SAG protein mixture with the antibody of Claim 23;
(c) isolating the antibody-SAG protein-RNA complexes; and (d) purifying the RNA away from the antibody-SAG protein complex.

28. A method of isolating RNA containing stretches of polyU residues, comprising (a) contacting an RNA sample with SAG protein in RNA binding buffer in the absence of reducing agents;
(b) incubating the RNA-SAG protein mixture with the antibody of Claim 23;
(c) isolating the antibody-SAG protein-RNA complexes; and (d) purifying the RNA away from the antibody-SAG protein complex.

29. A method for isolating genes induced during cell apoptosis, comprising:
(a) treating one set of cells with OP and not treating a control set of cells;
(b) isolating RNA from each set of cells;
(c) subjecting the RNA from each set of cells to the differential display procedure, wherein the RNA is reverse transcribed into cDNA and the cDNA is subjected to the polymerase chain reaction;
(d) identifying cDNAs that are expressed in the OP-treated set of cells and not in the control set of cells; and (e) cloning the OP-induced cDNAs.

30. A method for protecting cells from apoptosis induced by redox reagents, comprising introducing into the cells an expression vector comprising the isolated and purified DNA
sequence of Claim 1, 2, 3, 7, 8, 9, or 15, which is operatively linked to a DNA sequence that promotes the high level expression of the isolated and purified DNA sequence in the cells.

31. A method for inhibiting the growth of tumor cells, comprising introducing into the tumor cells an expression vector comprising the isolated and purified DNA
sequence of Claim 1, 2, 3, 7, 8, 9, or 15, which is operatively linked to a DNA sequence that promotes the high level expression of the antisense strand of the isolated and purified DNA
sequence in the cells.

32. A method for purifying SAG protein from bacterial cells comprising:
a) transfecting a bacterial host cell with a vector comprising the isolated and purified DNA sequence of Claim 1, 2, 3, 7, 8, 9, or 15 operatively linked to a promoter capable of directing gene expression in a bacterial host cell;
b) inducing expression of the isolated and purified DNA sequence in the bacterial cells;
c) lysing the bacterial cells;
d) isolating bacterial inclusion bodies;
e) purifying SAG protein from the isolated inclusion bodies.

33. A pharmaceutical composition comprising the substantially purified recombinant polypeptide of Claim 18, 19, 20, 21, or 22 and a pharmaceutically acceptable carrier.

34. The pharmaceutical composition of Claim 33 wherein the substantially purified recombinant polypeptide comprises an oligomer.

35. A method of oxygen radical scavenging in an organism comprising administering an oxygen radical -reducing amount of the pharmaceutical composition of Claim 33 or 34 to the organism.

36. A method of promoting the healing of a wound comprising administering the DNA
sequence of Claim 1 to cells associated with the wound.

37. A method of promoting or inhibiting the growth of plant cells comprising administering the DNA sequence of Claim 1 or a DNA sequence which is complementary to the DNA sequence of Claim 1 to plant cells.